POPULARITY
4 episodes with Baxter International
3 episodes with Baxter International
3 episodes with Baxter International
4 episodes with Baxter International
2 episodes with Baxter International
2 episodes with Baxter International
2 episodes with Baxter International
2 episodes with Baxter International
2 episodes with Baxter International
Join us for a discussion about authenticity and relatability as the foundation of effective leadership. Kyle McDowell is the bestselling author of "Begin With WE." One of my favorite parts of this episode is when he explains his system for setting clear expectations and inspiring people to do great work. You can get the Magnetic Systems Method (and other systems guides) to find issues before they become expensive problems. Highlights from the show: 1. Importance of authenticity and relatability in leadership Kyle discusses how he has always believed that authenticity and relatability are the foundation of effective leadership. He shares how he has focused on connecting with the people he leads, rather than just the processes and procedures, in order to build trust and enable their success. 2. Establishing clear expectations and enabling employee success He explains his approach to setting clear expectations with his team members during onboarding, and then working to remove any obstacles or roadblocks that prevent them from being successful. He emphasizes the importance of having open conversations to understand what each person needs from him as a leader. 3. Inspiring and motivating the team through challenges He discusses how he inspires and motivates his team, not just by focusing on metrics and results, but by understanding the personal and professional challenges they face. He shares a story about owning up to a $10 million mistake and how that built trust and loyalty with his team. 4. The 10 "We" principles for building a culture of excellence He outlines the 10 "We" principles he has developed to build a culture of excellence, including doing the right thing, leading by example, owning mistakes, and challenging each other. He explains how these principles have become embedded in the culture of the organizations he has led. 5. Influential leaders who shaped Kyle's approach He shares two leaders who have significantly influenced his leadership approach - Harry Kramer, the former CEO of Baxter International, and William Krenz, a COO he reported to earlier in his career. He discusses the valuable lessons he learned from each of them about the importance of values-based leadership and caring for employees as people. Learn more about Kyle McDowell over at his website. You can also connect with him on LinkedIn. As always, if you have any questions or want to submit an amazing guest for the podcast, just reach out to me on the Systematic Leader website, and I'll do my best to get them on. If you enjoy the interview, please take 30 seconds to rate the Systematic Leader podcast on your favorite platform. Thanks!
Crain's health care reporter Katherine Davis discusses recent leadership moves at Baxter International and Howard Brown Health with host Amy Guth.Plus: Pritzker takes aim at Team Trump over immigration — and Lake Illinois, McDonald's sales improve on stronger international results, Rivian broadens sales of plug-in van once exclusive to Amazon and Lurie Children's pauses gender-affirming surgeries following Trump administration threat.
Broadcast from KSQD, Santa Cruz on 11-14-2024: Dr. Dawn discusses a severe national IV fluid shortage caused by Hurricane Helene's flooding of a Baxter International factory which has affected hospital operations and surgical schedules nationwide. She provides a comprehensive explanation of cystic fibrosis, detailing how genetic mutations affect mucus production and impact multiple body systems, particularly the lungs and digestive system. The show explores the daily challenges faced by cystic fibrosis patients and their families, from complex treatment routines to social and financial impacts. Dr. Dawn presents exciting breakthroughs in cystic fibrosis treatment, including new CFTR modulators, targeted antibiotics, and promising developments in stem cell therapy and genetic treatments. She discusses a new universal genomic test developed at UCSF that can identify nearly any pathogen in cerebrospinal fluid, potentially revolutionizing the diagnosis of neurological infections. Dr. Dawn advises a caller about retinal dystrophy, explaining the differences between various eye conditions and suggesting potential dietary and lifestyle interventions. The show concludes with a concerning report about the tenfold increase in congenital syphilis cases over the past decade.
Feeling parched?Well, you're not alone. Hospitals across the country are dealing with a saline shortage.Thanks to Hurricane Helene's unwelcome visit to the Baxter International facility in North Carolina, your IV bags may be running low. Imagine a busy highway suddenly reduced to a single lane: that's what this IV shortage feels like for impacted healthcare providers.During the next live edition of the long-running and popular live Internet radio program Talk Ten Tuesday, Dr. Nick van Terheyden will report on just about everything related to this topic, from switching to oral meds (because who needs a needle when you can swallow?) to challenging those pesky “keep the veins open” (KVO) orders (seriously, do you really need to keep those veins open all the time?)Join Talk Ten Tuesdays and leave feeling hydrated and empowered!Also part of the broadcast, these instantly recognizable panelists will report more news during their segments:• The Coding Report: Christine Geiger, Assistant Vice President of Acute and Post-Acute Coding Services for First Class Solutions, will continue with the final installment in her three-part series on the significant changes in the newly released ICD-10 codes.• RegWatch: Former Centers for Medicare & Medicaid Services (CMS) career professional Stanley Nachimson will report on the latest regulatory news coming out of Washington, D.C.• Social Determinants of Health: Tiffany Ferguson, CEO for Phoenix Medical Management, Inc., will report on the news that is happening at the intersection of medical record auditing and the SDoH.• News Desk: Timothy Powell, ICD10monitor national correspondent and regulatory expert, will anchor the Talk Ten Tuesdays News Desk.• TalkBack: Erica Remer, MD, founder and president of Erica Remer, MD, Inc., and Talk Ten Tuesdays co-host, will report on a subject that has caught her attention during her popular segment.Cozen O'Connor Public Strategies - The Beltway BriefingListen for of-the-moment insider insights, framed by the rapidly changing social and...Listen on: Apple Podcasts Spotify
Rubberband LIVE - The Australian Recruitment and Talent Acquisition Podcast
GUEST: Suzann Cooper - POSITION: Regional Talent Acquisition Manager, ANZ, China and Japan - COMPANY: Baxter International - TOPIC: Recruitment Chinwag - FORMAT: Podcast Support the showJoin RUBBERBAND today!Check out: JobTetris Mercu
Where did Hurricane Helene hit? Why is there a shortage of intravenous fluids? What can I use instead of IV saline? Where are IV bags made? AMA's Vice President of Science, Medicine and Public Health, Andrea Garcia, JD, MPH, discusses the impact of Hurricane Helene, how elective surgery can be delayed after the North Carolina hurricane damage, and addressing drug shortages in the US. American Medical Association CXO Todd Unger hosts.
About Alan MatherAlan Mather is the President of the Golden Apple Foundation. In partnership with Alicia Winckler, the CEO, Alan leads the education work of the Foundation. Prior to coming to Golden Apple, Alan served in the Chicago Public Schools for more than 32 years, from classroom teacher to principal to a key member of the CEO and Chief Education Officer's cabinet--leading College and Career Success for the district. Born and raised in rural Southern Indiana, Alan hitchhiked up to Chicago after graduating from the University of Evansville in 1986 and has been working in the Chicago public schools ever since. Alan worked for 12 years as an English teacher, track and cross country coach before moving into administration after joining LAUNCH (Leadership and Urban Network for Chicago), the first principal preparation program in Chicago. His first administrative position was as the assistant principal at a new high school, Northside College Prep, which--in three years--became the top ranked high school in Illinois. In 2005, Alan was given the opportunity, as principal, to open Lindblom Math & Science Academy, a school that had once been top-tier but had declined. With the freedom, flexibility and support to create a high school, Alan hired all teachers, built a culture of excellence, and created an empowering climate. Since Alan opened Lindblom, it has become, according to the Sun-Times rankings, the top-performing majority AfricanAmerican school in Illinois and the only top 20-ranked school that has over 60% of its students on free/reduced lunch. He built the district's largest Mandarin program, the largest non-heritage Arabic program in the United States, and the district's first Biotechnology program in partnership with Baxter International and Northwestern University. Alan represented the Chicago Public Schools at Harvard University's PELP (Public Education Leadership Program), was an inaugural member of the College Board's Leadership Institute for Principals, has been part of Northwestern's Kellogg School of Management's “Leading Successful Schools” program, and was selected as one of two Chicago principals to participate in Columbia University's Cahn Fellows Distinguished Principals Program for the 2012-2013 school year at Teachers College. He was the first recipient of the Golden Apple Foundation's Stanley C. Golder Excellence in Leadership Award for Principals or Heads of School.About Alicia WincklerAlicia Winckler, Chief Executive Officer, began consulting with senior leadership and the Board of The Golden Apple Foundation in late 2014; was selected as its first President and Chief Operating Officer in January of 2017; and was selected as its President and Chief Executive Officer in October of 2017. In 2018, she welcomed Alan Mather to join her in coleading the Foundation - with Alicia as CEO and Alan becoming President. Her professional experience reflects a unique combination of private, public and nonprofit sector expertise at both the executive and board level, as well as a demonstrated passion for serving others. Alicia led several substantial strategic initiatives at the Cabinet level of the nation's third largest K-12 District - in Chicago Public Schools - and has been working in depth in education for more than a decade. She earned her M.A. in Industrial / Organizational Psychology from the University of Colorado at Denver and B.S. in Psychology and Alcohol and Drug Abuse Studies from the University of South Dakota.The Golden Apple FoundationGolden Apple LinkedInGolden Apple FacebookGolden Apple InstagramGolden Apple XAlan Mather- Award Video Thank you for listening to "Can You Hear Me?". If you enjoyed our show, please consider subscribing and leaving a review on your favorite podcast platform.Stay connected with us:Follow us on LinkedIn!Follow our co-host Eileen Rochford on Linkedin!Follow our co-host Rob Johnson on Linkedin!
Steve Grzanich has the business news of the day with the Wintrust Business Minute. Deerfield-based Baxter International says Hurricane Helene could cause a shortage of IV fluids that could last months. The company says its largest manufacturing plant in North Carolina was hard hit last month by the storm. It could take until the end […]
Thanks to the TIN FOIL MULISHA members who support this podcast with their time, talent and treasure! Support UFO...No! with a direct PayPal donation: https://www.paypal.com/paypalme/ufonopodcast/5 Join the UFO...No! Patreon: https://www.patreon.com/ufonopodcast Join the UFO...No! Discord: https://discord.gg/QysDepDu9P Buy UFO...No! Merch: https://ufono-podcast.creator-spring.com Looking for Magic Mushrooms (Psilocybin)? Visit https://www.schedule35.co/us/ Use code U1173687US240607 to get a 20% discount on your first purchase! SHOW NOTES https://www.youtube.com/shorts/q28gazfNP4I https://www.youtube.com/watch?v=LiyEOZ-OOZo&t=40s https://www.youtube.com/watch?v=5fH0cYn52eg FACTS & FUCKERY Flood footage 1 https://x.com/volcaholic1/status/1841422096641019942 Flood footage 2 https://x.com/Ella__Dorsey/status/1841500310629462132 Flood footage 3 https://x.com/ReedTimmerUSA/status/1841302019077767308 Gov sabotage 1 https://x.com/RealDrJaneRuby/status/1841284095101305054 Gov sabotage 2 https://x.com/WallStreetApes/status/1841433497124417934 Gov sabotage 3 https://x.com/WallStreetApes/status/1841496400020058321 Gov sabotage 4 https://x.com/WallStreetApes/status/1841529001938190614 Gov sabotage 5 https://x.com/Skriptkeeper17/status/1841448651127693359 Gov sabotage 6 https://x.com/ShadowofEzra/status/1841679099959320871 Gov sabotage 7 https://x.com/atensnut/status/1841865609279070388 Gov sabotage 8 https://x.com/WatchChad/status/1841843962534826165 Local authorities threatening citizens 1 https://x.com/WallStreetApes/status/1841848160995467506 Local authorities threatening citizens 2 https://x.com/RealDrJaneRuby/status/1841454435416875412 Gov says no aid 1 https://nypost.com/2024/10/03/us-news/feds-say-theres-no-money-left-to-respond-to-hurricanes-after-fema-used-640-9m-this-year-on-migrants/?utm_medium=social&utm_source=twitter&utm_campaign=nypost Gov says no aid 2 https://x.com/VigilantFox/status/1841474139128762433 Gov says no aid 3 https://x.com/EndWokeness/status/1840597990760649031 Gov asks Americans to pay for aid https://x.com/ChuckCallesto/status/1840966490649960714 Other countries are more important https://x.com/IsabellaMDeLuca/status/1841670489141346404 Trump seems to be helping https://x.com/ChuckCallesto/status/1841142521663029417 Americans are amazing 1 https://x.com/ryantyre/status/1841583311782568064 Americans are amazing 2 https://x.com/dagenmcdowell/status/1841648583663046741 Americans are amazing 3 https://x.com/CoryMillsFL/status/1841491571461829013 Americans are amazing 4 https://x.com/Mashburn4NC/status/1841207336393678925 Americans are amazing 5 https://x.com/TheShawnHendrix/status/1841835579761139730 Baxter International temporarily closes its largest plant following hurricane, raising questions about supply of medical solutions https://www.hastingstribune.com/ap/business/baxter-international-temporarily-closes-its-largest-plant-following-hurricane-raising-questions-about-supply-of-medical/article_dafa4dd2-a318-5d6b-80cb-b31bd94a5818.html
Thanks to the TIN FOIL MULISHA members who support this podcast with their time, talent and treasure! Support UFO...No! with a direct PayPal donation: https://www.paypal.com/paypalme/ufonopodcast/5 Join the UFO...No! Patreon: https://www.patreon.com/ufonopodcast Join the UFO...No! Discord: https://discord.gg/QysDepDu9P Buy UFO...No! Merch: https://ufono-podcast.creator-spring.com Looking for Magic Mushrooms (Psilocybin)? Visit https://www.schedule35.co/us/ Use code U1173687US240607 to get a 20% discount on your first purchase! SHOW NOTES https://www.youtube.com/shorts/q28gazfNP4I https://www.youtube.com/watch?v=LiyEOZ-OOZo&t=40s https://www.youtube.com/watch?v=5fH0cYn52eg FACTS & FUCKERY Flood footage 1 https://x.com/volcaholic1/status/1841422096641019942 Flood footage 2 https://x.com/Ella__Dorsey/status/1841500310629462132 Flood footage 3 https://x.com/ReedTimmerUSA/status/1841302019077767308 Gov sabotage 1 https://x.com/RealDrJaneRuby/status/1841284095101305054 Gov sabotage 2 https://x.com/WallStreetApes/status/1841433497124417934 Gov sabotage 3 https://x.com/WallStreetApes/status/1841496400020058321 Gov sabotage 4 https://x.com/WallStreetApes/status/1841529001938190614 Gov sabotage 5 https://x.com/Skriptkeeper17/status/1841448651127693359 Gov sabotage 6 https://x.com/ShadowofEzra/status/1841679099959320871 Gov sabotage 7 https://x.com/atensnut/status/1841865609279070388 Gov sabotage 8 https://x.com/WatchChad/status/1841843962534826165 Local authorities threatening citizens 1 https://x.com/WallStreetApes/status/1841848160995467506 Local authorities threatening citizens 2 https://x.com/RealDrJaneRuby/status/1841454435416875412 Gov says no aid 1 https://nypost.com/2024/10/03/us-news/feds-say-theres-no-money-left-to-respond-to-hurricanes-after-fema-used-640-9m-this-year-on-migrants/?utm_medium=social&utm_source=twitter&utm_campaign=nypost Gov says no aid 2 https://x.com/VigilantFox/status/1841474139128762433 Gov says no aid 3 https://x.com/EndWokeness/status/1840597990760649031 Gov asks Americans to pay for aid https://x.com/ChuckCallesto/status/1840966490649960714 Other countries are more important https://x.com/IsabellaMDeLuca/status/1841670489141346404 Trump seems to be helping https://x.com/ChuckCallesto/status/1841142521663029417 Americans are amazing 1 https://x.com/ryantyre/status/1841583311782568064 Americans are amazing 2 https://x.com/dagenmcdowell/status/1841648583663046741 Americans are amazing 3 https://x.com/CoryMillsFL/status/1841491571461829013 Americans are amazing 4 https://x.com/Mashburn4NC/status/1841207336393678925 Americans are amazing 5 https://x.com/TheShawnHendrix/status/1841835579761139730 Baxter International temporarily closes its largest plant following hurricane, raising questions about supply of medical solutions https://www.hastingstribune.com/ap/business/baxter-international-temporarily-closes-its-largest-plant-following-hurricane-raising-questions-about-supply-of-medical/article_dafa4dd2-a318-5d6b-80cb-b31bd94a5818.html
Harry Kraemer is an executive partner with Madison Dearborn Partners, a private equity firm based in Chicago, and a Clinical Professor of Leadership at Northwestern University's Kellogg School of Management. He previously served as chairman and CEO of Baxter International, a $12 billion global healthcare company. He is also the author of three bestselling leadership books and a sought-after speaker. Harry joined host Robert Glazer on the Elevate Podcast to discuss his leadership career, why self-awareness is essential to leadership, tips for success as a CEO, and more. Learn more about your ad choices. Visit megaphone.fm/adchoices
In this episode of the DeviceTalks Weekly Podcast, Host Tom Salemi chats with Managing Editor Kayleen Brown about the upcoming DeviceTalks West meeting. This week's episode features an interview Brown did with Medtronic's Nina Goodheart at the Women in Medtech Breakfast at DeviceTalks Boston. The conversation previews the Women in Medtech Luncheon interview featuring Cecilia Soriano, president, infusion therapies and technologies, at Baxter International. In our second interview, Salemi interviews Kirsten Carroll, CEO of Kandu Health about that company's work to empower stroke survivors. Carroll will be speaking at DeviceTalks West. Register at West.DeviceTalks.com to register. Use the code DTPOD25 to save 25%. Subscribe now to the DeviceTalks Podcast Network.
Welcome, MedTech Gurus! Today, we have an incredible guest: Anupam Girdha, CEO of Ascential Technology's Medical and Life Sciences Division. Ascential is a leader in innovating and automating complex diagnostics and test processes across various industries. With over 70 years of experience and 2,300 experts worldwide, they're unstoppable in tackling mission-critical challenges and driving breakthroughs. Anupam, with key roles at Thermo Fisher Scientific, Baxter International, and ZS Associates, shares his journey of scaling manufacturing during COVID-19 and turning innovation into reality with Ascential's cutting-edge antimicrobial testing. Get ready for an electrifying episode packed with insights and innovation!
In this episode, Scott Becker discusses essential investment rules, including the importance of not panic selling and having an emergency fund & covers significant market movements of companies like Rivian, Tempus AI, and Baxter International, as well as political updates with Kamala Harris and Corey Bush.
In this episode, Scott Becker discusses essential investment rules, including the importance of not panic selling and having an emergency fund & covers significant market movements of companies like Rivian, Tempus AI, and Baxter International, as well as political updates with Kamala Harris and Corey Bush.
Bienvenidos a un nuevo Spaces en directo mientras unos millonarios en pantalón corto dan patadas a un balón. Hoy vamos a abordar un tema delicado: la salud, un campo de batalla en la confrontación entre las élites psicopatocráticas y la humanidad. La fragmentación social ha generado no solo dos enfoques principales —los remedios naturales y los tratamientos de la industria farmacéutica— sino una amplia gama de posibilidades intermedias. La locura colectiva desatada por la supuesta epidemia de COVID a nivel mundial ha evidenciado que la industria farmacéutica parece más interesada en crear clientes futuros que en curar enfermedades. Las patologías cardiovasculares, el cáncer y las enfermedades neurodegenerativas han aumentado tras las vacunaciones, lo cual es innegable. Sin embargo, este aumento sigue siendo proporcionalmente insignificante en comparación con el número total de personas vacunadas. Pedro Bustamante en su primera obra “El imperio de la ficción.Capitalismo y sacrificios hollywoodenses” nos dice lo siguiente: “Hoy cada vez más el modus operandi del imperio es vendernos mentiras con el envoltorio de «verdades» oficiales. Esta es, como veremos, una de sus muchas ficciones. Estas mentiras se fabrican en buena medida de manera encubierta, y en muchos casos no es posible comprobar si nos están mintiendo, pues todo se reduce a la lógica del «esto es así porque lo digo yo» (que soy el que manda, el que oculta o desvela ( la información).” La narrativa sobre las vacunas contra la COVID ha estado llena de interrogantes. Hoy en día sabemos que estas vacunas estaban preparadas mucho antes de que comenzara la supuesta pandemia. Tampoco podemos estar seguros de sus componentes exactos, a pesar de las afirmaciones de algunos científicos que se identificaban como parte de la disidencia, quienes decían que contenían grafeno y otros elementos dañinos. Esos mismos científicos, durante la campaña del COVID, participaban en publirreportajes sobre lo malísimo que es el cambio climático. Sospechamos que el miedo fue el verdadero causante de muchas muertes. Según el doctor Hammer, el miedo puede bloquear las vías respiratorias. Este miedo, sumado a la temporada de gripe y a las pruebas PCR, creó lo que desde Buscadores llamamos la "Tragipandemia". Actualmente, el temor a los componentes de las vacunas está generando otra ola de enfermos. Nosotros, como buscadores de la verdad, hemos hablado claramente desde el principio sobre nuestras opiniones al respecto. Sin embargo, no hemos tenido la influencia y el reconocimiento que sí han obtenido voces críticas como el biólogo Fernando López-Mirones, la Dra. Nadiya Popel, la Dra. Natalia Prego, la Dra. María José Albarracín y otros médicos españoles asociados en "Médicos por la Verdad". Este grupo es una especie de franquicia mundial que agrupa a médicos que no siguen las directrices oficiales. Todos ellos han enfrentado persecución por defender sus ideas y algunos, como la Dra. Popel, han sido llevados a juicio. Sin embargo, es importante notar cómo estas personas difunden el miedo. La Dra. Popel, por ejemplo, está intentando establecer un sistema sanitario alternativo, afirmando la inminente desaparición del sistema sanitario actual. Así lo declaró en un podcast titulado “Nadiya Popel: La seguridad social va a colapsar en junio de 2024”. Estas declaraciones son del 2023 y, hasta ahora, la seguridad social sigue operando, aunque con muchas fallas. El biólogo Fernando López-Mirones aseguraba ufano en julio de 2020, durante la pandemia que "Cada persona contagia a cuatro” y que “todas las personas que vinieran a España debían hacerse un PCR”. No contento con eso en noviembre de 2020 pedia que todo el mundo se metiese el palito por la nariz. No le diremos por donde se puede meter el palito. Pero si alguien infundio miedo de alto nivel fue la Dra Maria Jose Albarracín con sus declaraciones sobre la muerte de un 30% de la población vacunada durante el invierno de 2020. En Murcia hacia estas declaraciones sobre lo que pasaría para el otoño invierno del 2021: “Por lo tanto, a partir del próximo otoño-invierno, si la primera ola asustó a urgencias y produjo mucha mortalidad, lo que vamos a ver a partir del otoño-invierno que viene no va a tener precedentes. Vamos a ver morir por decenas de miles a las personas principalmente vacunadas, pero los vacunados contagian, por lo tanto la epidemia puede ser muy extensa. Si ahora se han tomado un montón de medidas restrictivas y se nos ha quitado la libertad por apenas una pequeña epidemia, cuando la epidemia sea de verdad, producida por las variantes que inducen las vacunas, al combinar la proteína espiga con nuestros virus endógenos, entonces ¿qué va a ser? Ya no va a haber posibilidad de reacción y la dictadura va a ser total. Quizá solucionen eso con una guerra…” He de decir que en octubre de 2020 yo estaba de acuerdo con las afirmaciones de la Dra Albarracín sobre que estas llamadas vacunas tenían una alta toxicidad y patogenocidad e incluso sobre que podían producir cáncer. Eso no lo discutimos. Pero al igual que existe el placebo que sabemos han usado en las vacunas covid, existe el efecto nocebo que se da entre otros factores cuando creemos que algo malo va a suceder. Fue en abril de 2021 cuando escuchamos las declaraciones mas duras de la Dra Albarracín en el programa el gato al agua. Allí la doctora hablaba de expertos que auguraban una enorme mortandad entre los vacunados, se refería veladamente al informe con las previsiones oficiales del gobierno británico y del que también hablamos nosotros: “Y, por lo tanto lo que se va a producir es una enfermedad aumentada por vacunas. Es decir, va a haber epidemias mayores más extensas y más graves porque el sistema inmune va a estar mal condicionado. Y eso ya se sabe, ya se sabe que hay vacunas como la del dengue que ha producido estos problemas. Y se sabe, cuando se han ensayado contra el coronavirus o contra el virus inicial respiratorio que producen estos problemas. Por lo tanto, en el hemisferio norte el próximo otoño-invierno vamos a ver una ola epidémica muy superior con mayor gravedad y con mayor mortalidad. Estiman los expertos que entre el 20 y el 30% de los vacunados morirán. No queremos ser agoreros, pero realmente si se consigue alcanzar este 70% de vacunación que se quiere para el otoño alcanzamos lo que se llama un umbral de percolación o un umbral de epidemia porque los vacunados contagiarán también a los no vacunados y, por lo tanto se producirá una epidemia extensa y grave…”. Estamos hablando de que supuestamente se iba a producir una especie de pandemia zombie donde todos terminaríamos enfermando no ya por un virus inexistente sino por una proteínas voladoras asesinas que contagiaban, unas proteínas, por cierto que tenemos por todas partes en muchas de nuestras células y las células de los microbios, vida pluricelar y parasitos que nos componen. Ricardo, de la quinta columna, dijo esto en Octubre del 2021 en un programa externo donde por suerte había un periodista, justo por las fechas que la Dra Albarracin pronosticaba que moriría el 30% de la población vacunada: “…Hoy publicaba el Reino Unido que el 80% de las personas que habían sido vacunadas ya han fallecido. Y cómo fallecen. Porque no lo hacen de forma instantánea.” Afortunadamente el periodista con el que estaba conversando le pregunta esto: “¿Cómo qué el 80% de las personas que han sido vacunadas han fallecido?” Respondiendo Ricardo: “Con la pauta completa, efectivamente.” Contestandole de forma ironica el periodista: “Entonces, habría muerto prácticamente medio Reino Unido.” Termina Ricardo diciendo: “Bueno, medio Reino Unido si las cifras son correctas, al menos, eso lo publica The Daily Expose.” El periodista le insiste en que debe ser un error: “Pero bueno, eso, lógicamente esa noticia hay que ponerla entre comillas, porque, lógicamente eso no ha sucedido, no.” No estamos hablando de unos cuantos cientos o miles de muertos, el 80% de la población vacunada de Reino Unido son millones de personas. He de decir que luego Ricardo reconoció este error. Realmente daba igual ya que se había dedicado y se dedica a introducir el miedo en todas las personas que se han vacunado contándoles una historia de terror, donde el grafeno y el 5G se dan la mano. Nosotros no hemos creído en la existencia de un virus que provocase el Covid como no creemos en la existencia de ningún virus, y por tanto es imposible que algo que no existe cree una pandemia. Si que creemos en la existencia de la posibilidad de estar siendo envenenados con todo tipo de sustancias salvo la que estuvo en boca de todos, el grafeno. Ya saben, esos grupos de carbono que crean estructuras moleculares en forme de hexágono de las que el supuesto Dr Andreas Noack decía que formaban cuchillas de hidróxido de grafeno que circulaban por nuestro sistema circulatorio cortándolo desde dentro. Todas nuestras células tienen estructuras que acaban en átomos y muchas moléculas como por ejemplo los colorantes adoptan formas en forma de cuchilla…y no, no nos cortan por dentro, aunque como yo he contado en mas de una ocasión incluso se pueden quedar atrapadas en las estructuras que replican el ADN dentro de nuestras células…es muy difícil pero no imposible. "Grafeno (átomos de carbono, nuestra materia misma) que se comporta como cuchillas de afeitar." "Trozos de proteínas que se pueden contagiar." "Proteínas que utilizamos en infinidad de sistemas dentro de nuestro cuerpo que nos pueden enfermar." No, no creo que eso sea ciencia. Asi es como se las gasta la “reliciencia” mezcla entre religión y ciencia que impone el poder global. Desde luego la misteriosa desaparición del supuesto Dr Andreas Noack, del que no hay datos que corroboren que sea científico, ocultan las verdaderas brutalidades del sistema como la ocurrida al cardiólogo suizo Dr. Thomas Binder. Este fue internado en un psiquiátrico por decir la verdad sobre el Covid19. Como condición para su puesta en libertad, le obligaron a tomar una medicación psiquiátrica. Esto no es la primera vez que ocurre. Jane Burgermeister, la periodista austriaca que destapó lo que ocurrió en el 2009 con la gripe porcina también fue ingresada en un psiquiátrico tras denunciar los planes de vacunación masiva de la gripe aviar en 2009. Jane Burgermeister es una periodista especializada en salud que ha trabajado para el British Medical Journal, Nature, The Scientist, Reuters, The Guardian y otros medios. En 2009, descubrió que la farmacéutica Baxter International había enviado material para vacunas contaminado con virus aviar vivo, sin atenuar, a 18 laboratorios en varios países europeos. En total, se trataba de 72 kilos de virus de la gripe mezclados con el mortal virus de la gripe aviar en sus instalaciones de nivel de bioseguridad BSL-3 en Austria. Esta contaminación fue detectada por el laboratorio checo BioTest al probar los viales con animales, que murieron pocas horas después. Este hallazgo llevó a Burgermeister a iniciar una investigación en la que recopiló numerosas evidencias y pruebas. Con esta información, presentó denuncias ante los tribunales contra diversas agencias e instituciones, como la OMS, la ONU, Baxter International, la FDA, el gobierno estadounidense y varios gobiernos europeos, así como contra banqueros, acusándolos de intento de genocidio y bioterrorismo mediante la vacunación contra la gripe. Finalmente, fue demandada, y un juez intentó declararla incapaz para poder enviarla a un psiquiátrico. Os voy a leer textual un trozo de uno de sus artículos de su ya desaparecido blog, para que podáis juzgar si estaba loca o no. En dicho texto nos habla de una entrevista que mantuvo con la unidad antiterrorista de Austria por sostener que una supuesta explosión inofensiva de un vial de gripe porcina en un tren en Lausana fue un acto deliberado. Dice así: “Cualquiera que piense que la idea de que la OMS y otros están liberando deliberadamente virus pandémicos es una teoría de la conspiración debería tener en cuenta que la unidad antiterrorista de Austria (BVT) me convocó para una entrevista de dos horas el 5 de julio de 2009 sobre los cargos que presenté sobre bioterrorismo del incidente en Suiza. La invitación de BVT decía Escuela internacional porque la entrevista fue principalmente sobre el incidente del tren y no sobre la contaminación de 72 kilos en Baxter de virus de la gripe con el mortal virus de la gripe aviar en sus instalaciones BSL3 en Austria. Aquí hay una copia de mis cargos del 1 de mayo de 2009 en alemán. Los profesionales tomaron en serio los cargos debido a los hechos, detalles del incidente que no pueden ser explicado a menos que asuma que fue un acto deliberado. Mis cargos alegan un incidente de bioterrorismo en Suiza el 29 de abril de 2009 cuando un contenedor "defectuosamente" lleno con viales de "gripe porcina", supuestamente directo de la Ciudad de México, y un laboratorio afiliado a la OMS, explotó en un tren Inter City abarrotado cerca de Lausana. Rociando a los pasajeros con el agente biológico mientras el contenedor era transportado a través de Suiza hasta el laboratorio nacional de gripe de Ginebra. El contenedor explotó con tanta fuerza que el técnico de laboratorio que lo transportaba y algunos de los pasajeros resultaron heridos. En el compartimento del tren había 61 personas expuestas al virus. Alegué que el contenedor herméticamente cerrado con hielo seco defectuoso era en realidad una bomba de cabon tipo "mochila" diseñada para evadir los detectores electrónicos en el aeropuerto y la estación de Zurich, y para explotar en un momento específico en los compartimentos climatizados del tren: un espacio relativamente cerrado con temperatura constante, etc. un ambiente ideal para esparcir un agente aerolizado por la fuerza de la explosión. El contenedor tenía 3 capas. La parte más interna contenía un frasco de gripe porcina. La segunda capa contenía hielo seco. La tercera capa era de sellado hermético. Cuando el hielo seco o el CO2 sólido se derrite, se convierte en gas. A medida que el hielo seco de la segunda capa del contenedor se derritió en el tren, el volumen de gas de la segunda capa aumentó y, por tanto, la presión sobre el vial. La detonación del contenedor se debió a la creciente presión del hielo seco que se evaporaba tanto en el vial en la parte más interna como en el contenedor más externo. De hecho, el hielo seco sirvió como detonador. El hielo seco se sublima. Cambia directamente de sólido a gas. Por lo tanto, los paquetes y sobreenvases no deben cerrarse herméticamente. Deben permitir que los gases escapen para evitar la acumulación de presión. • A medida que el hielo seco se sublima, crea gas dióxido de carbono, que es incoloro e inodoro. La idea de que un laboratorio pueda haber colocado accidentalmente hielo seco dentro del contenedor en lugar de afuera es increíble, simplemente. Tan increíble como tomar un tren Inter City para transportar muestras de virus consideradas lo suficientemente peligrosas como para causar una emergencia global, sin avisar a las autoridades ferroviarias suizas. Sostengo que se eligió el compartimento con aire acondicionado del tren Inter City porque, al igual que el interior de un avión, ofrece condiciones óptimas para el bioterrorismo ya que actúa en la medida en que la temperatura y las corrientes de aire permanecen bastante constantes, lo que permite cálculos más precisos. La explosión se produjo a las 18.39 en Friburgo y el tren fue detenido. Además, en primer lugar, los viales de gripe pandémica nunca deberían haber sido transportados en un tren de pasajeros, una clara violación de la ley. Los pasajeros pudieron regresar a sus casas sin ningún control médico gracias a la intervención de un funcionario del laboratorio nacional. En el momento de la explosión no se había registrado ni un solo caso de gripe "porcina" en Suiza. Mientras tanto, la gripe se está propagando lenta pero seguramente, lo que ayuda a la OMS a justificar su declaración de nivel 6 de pandemia. Los informes de Flutrackers muestran que la mayor incidencia de gripe "porcina" en Suiza se encuentra en el cantón de Vaud, Lausana, lugar del incidente del tren de la "gripe porcina". Una persona ha sido infectada dentro de Suiza; no está claro cómo pudo ocurrir. ¿Podría esa persona haber sido un pasajero en ese tren? Los principales medios de comunicación se apresuraron a descartar el incidente, diciendo que el virus de la gripe porcina era inofensivo. Pero si era tan inofensivo, ¿por qué la OMS alegaba una emergencia epidémica mundial?” Lo ultimo que sabemos de Jane es que tuvo que refugiarse en Grecia y borrar los dos blogs que tenia. Les he contado la historia de la periodista austriaca para que comprendan que, aunque trabajemos con buenas intenciones, nuestro trabajo puede ser usado para generar miedo, como ha sucedido en otros casos. Nosotros no creemos en la existencia de virus asesinos, sino en estructuras que transmiten información, como señala el científico Máximo Sandín. La ciencia oficial está descubriendo, por ejemplo, que dentro de ese 80% del ADN que anteriormente se consideraba "basura", hay cientos de virus... y esto ocurre en cada una de nuestras células. Así que hoy lucharemos contra los enemigos que vemos y los que no vemos, poniéndole el cascabel al gato. Ponerle el cascabel al gato puede significar enfrentarse a situaciones incómodas, resolver conflictos difíciles, tomar decisiones impopulares o enfrentar riesgos personales en nombre de un objetivo mayor. Informarnos e informar a otros de la llegada de un peligro o de la conveniencia o no de cierta decisión sirve para adelantarnos al golpe de ese enemigo o impedir ser dirigidos en la dirección que éste busca. Por eso los médicos debéis ser sinceros. La sinceridad es el pilar que sostiene la transparencia y la confianza en una sociedad. En un mundo cada vez más amenazado por la manipulación y el control, la verdad se convierte en nuestro único escudo contra la distopía. Al aferrarnos a la sinceridad, evitamos caer en la trampa de las ilusiones y los engaños que alimentan un futuro oscuro. Así, la honestidad no solo nos libera, sino que también actúa como la brújula que nos guía hacia un mundo más justo y humano. ………………………………………………………………………………………. Thomas Binder, Peter McCullough, Dr. Dean patterson, Dr. Vernon Coleman, Dr. Rich McCormick, doctora Kerryn Phelps, Dr Joseph Ladapo, Dra. Simone Gold, Leonardo González Bayona, Dr. Rashid Buttar. ………………………………………………………………………………………. Invitados: …. Dra Yane #JusticiaParaUTP @ayec98_2 Médico y Buscadora de la verdad. Con Dios siempre! No permito q me dividan c/izq -derecha, raza, religión ni nada de la Creación. https://youtu.be/TXEEZUYd4c0 …. UTP Ramón Valero @tecn_preocupado Un técnico Preocupado un FP2 IVOOX UTP http://cutt.ly/dzhhGrf BLOG http://cutt.ly/dzhh2LX Ayúdame desde mi Crowfunding aquí https://cutt.ly/W0DsPVq ………………………………………………………………………………………. Enlaces citados en el podcast: La libertad de ayudar: programa de ayuda a Manuel Jesús Rodríguez https://www.youtube.com/live/PZs5N_3OShk Dra. Nadiya Popel en Olot (16 Febrero 2024) https://www.ivoox.com/dra-nadiya-popel-olot-16-febrero-2024-audios-mp3_rf_124428201_1.html Nadiya Popel: La seguridad social va a colapsar en junio del 2024. https://www.ivoox.com/nadiya-popel-la-seguridad-social-va-a-colapsar-audios-mp3_rf_121285631_1.html Retratos de una historia NO contada: Ozonoterapia https://www.ivoox.com/retratos-historia-no-contada-ozonoterapia-audios-mp3_rf_122257080_1.html POR FIN PEDRO SÁNCHEZ HACE CASO AL BIÓLOGO : YA LO DIJE HACE CINCO MESES https://www.youtube.com/watch?v=VelFbxSc4v8 El biólogo Fernando López-Mirones: "España no terminará con el Covid19 hasta después del verano” https://www.youtube.com/watch?v=SpFWcbu2Tac Web del Dr Vernon Coleman https://vernoncoleman.com/ Desinformantes. Una herramienta contra los voceros de la mentira en la pandemia https://saludconlupa.com/series/desinformantes/ 30% mortandad pronosticado por la Dra Albarracin https://x.com/tecn_preocupado/status/1458902173589323776 La Dra Albarracín y otros expertos predicen un aumento impresionante de la mortandad entre personas vacunadas para este otoño https://x.com/tecn_preocupado/status/1383714700362326018 FLASHBACK A 2009 Y MI ENTREVISTA DE 2 HORAS CON LA UNIDAD ANTITERRORISTA DE AUSTRIA SOBRE EL ACTO DE BIOTERRORISMO DE LA OMS EN SUIZA https://web.archive.org/web/20210126013729/https://thefourthempire.blogspot.com/2020/02/flashback-to-2009-and-my-2-hour.html Un contenedor de virus explota en un tren interurbano https://web.archive.org/web/20091225054307/http://www.20min.ch/news/dossier/schweinegrippe/story/16556954 Contenedor con virus de la gripe explota en un tren https://web.archive.org/web/20090501124053/http://www.welt.de/wissenschaft/article3639195/Behaelter-mit-Grippeviren-im-Zug-explodiert.html Cuenta suspendida de Jane Burgermeister en Twitter https://x.com/constanzag77/status/1734239222905905400 Tejiendo la red de la vida (web de Maximo Sandin) https://somosbacteriasyvirus.com/ ………………………………………………………………………………………. Música utilizada en este podcast: Tema inicial Heros ………………………………………………………………………………………. Epílogo BUSCANDO LA VERDAD - RICKY CAMPANELLI & JIMMY BOSCH https://www.youtube.com/watch?v=uGXnpk4JUGk
Bienvenidos a un nuevo Spaces en directo mientras unos millonarios en pantalón corto dan patadas a un balón. Hoy vamos a abordar un tema delicado: la salud, un campo de batalla en la confrontación entre las élites psicopatocráticas y la humanidad. La fragmentación social ha generado no solo dos enfoques principales —los remedios naturales y los tratamientos de la industria farmacéutica— sino una amplia gama de posibilidades intermedias. La locura colectiva desatada por la supuesta epidemia de COVID a nivel mundial ha evidenciado que la industria farmacéutica parece más interesada en crear clientes futuros que en curar enfermedades. Las patologías cardiovasculares, el cáncer y las enfermedades neurodegenerativas han aumentado tras las vacunaciones, lo cual es innegable. Sin embargo, este aumento sigue siendo proporcionalmente insignificante en comparación con el número total de personas vacunadas. Pedro Bustamante en su primera obra “El imperio de la ficción.Capitalismo y sacrificios hollywoodenses” nos dice lo siguiente: “Hoy cada vez más el modus operandi del imperio es vendernos mentiras con el envoltorio de «verdades» oficiales. Esta es, como veremos, una de sus muchas ficciones. Estas mentiras se fabrican en buena medida de manera encubierta, y en muchos casos no es posible comprobar si nos están mintiendo, pues todo se reduce a la lógica del «esto es así porque lo digo yo» (que soy el que manda, el que oculta o desvela ( la información).” La narrativa sobre las vacunas contra la COVID ha estado llena de interrogantes. Hoy en día sabemos que estas vacunas estaban preparadas mucho antes de que comenzara la supuesta pandemia. Tampoco podemos estar seguros de sus componentes exactos, a pesar de las afirmaciones de algunos científicos que se identificaban como parte de la disidencia, quienes decían que contenían grafeno y otros elementos dañinos. Esos mismos científicos, durante la campaña del COVID, participaban en publirreportajes sobre lo malísimo que es el cambio climático. Sospechamos que el miedo fue el verdadero causante de muchas muertes. Según el doctor Hammer, el miedo puede bloquear las vías respiratorias. Este miedo, sumado a la temporada de gripe y a las pruebas PCR, creó lo que desde Buscadores llamamos la "Tragipandemia". Actualmente, el temor a los componentes de las vacunas está generando otra ola de enfermos. Nosotros, como buscadores de la verdad, hemos hablado claramente desde el principio sobre nuestras opiniones al respecto. Sin embargo, no hemos tenido la influencia y el reconocimiento que sí han obtenido voces críticas como el biólogo Fernando López-Mirones, la Dra. Nadiya Popel, la Dra. Natalia Prego, la Dra. María José Albarracín y otros médicos españoles asociados en "Médicos por la Verdad". Este grupo es una especie de franquicia mundial que agrupa a médicos que no siguen las directrices oficiales. Todos ellos han enfrentado persecución por defender sus ideas y algunos, como la Dra. Popel, han sido llevados a juicio. Sin embargo, es importante notar cómo estas personas difunden el miedo. La Dra. Popel, por ejemplo, está intentando establecer un sistema sanitario alternativo, afirmando la inminente desaparición del sistema sanitario actual. Así lo declaró en un podcast titulado “Nadiya Popel: La seguridad social va a colapsar en junio de 2024”. Estas declaraciones son del 2023 y, hasta ahora, la seguridad social sigue operando, aunque con muchas fallas. El biólogo Fernando López-Mirones aseguraba ufano en julio de 2020, durante la pandemia que "Cada persona contagia a cuatro” y que “todas las personas que vinieran a España debían hacerse un PCR”. No contento con eso en noviembre de 2020 pedia que todo el mundo se metiese el palito por la nariz. No le diremos por donde se puede meter el palito. Pero si alguien infundio miedo de alto nivel fue la Dra Maria Jose Albarracín con sus declaraciones sobre la muerte de un 30% de la población vacunada durante el invierno de 2020. En Murcia hacia estas declaraciones sobre lo que pasaría para el otoño invierno del 2021: “Por lo tanto, a partir del próximo otoño-invierno, si la primera ola asustó a urgencias y produjo mucha mortalidad, lo que vamos a ver a partir del otoño-invierno que viene no va a tener precedentes. Vamos a ver morir por decenas de miles a las personas principalmente vacunadas, pero los vacunados contagian, por lo tanto la epidemia puede ser muy extensa. Si ahora se han tomado un montón de medidas restrictivas y se nos ha quitado la libertad por apenas una pequeña epidemia, cuando la epidemia sea de verdad, producida por las variantes que inducen las vacunas, al combinar la proteína espiga con nuestros virus endógenos, entonces ¿qué va a ser? Ya no va a haber posibilidad de reacción y la dictadura va a ser total. Quizá solucionen eso con una guerra…” He de decir que en octubre de 2020 yo estaba de acuerdo con las afirmaciones de la Dra Albarracín sobre que estas llamadas vacunas tenían una alta toxicidad y patogenocidad e incluso sobre que podían producir cáncer. Eso no lo discutimos. Pero al igual que existe el placebo que sabemos han usado en las vacunas covid, existe el efecto nocebo que se da entre otros factores cuando creemos que algo malo va a suceder. Fue en abril de 2021 cuando escuchamos las declaraciones mas duras de la Dra Albarracín en el programa el gato al agua. Allí la doctora hablaba de expertos que auguraban una enorme mortandad entre los vacunados, se refería veladamente al informe con las previsiones oficiales del gobierno británico y del que también hablamos nosotros: “Y, por lo tanto lo que se va a producir es una enfermedad aumentada por vacunas. Es decir, va a haber epidemias mayores más extensas y más graves porque el sistema inmune va a estar mal condicionado. Y eso ya se sabe, ya se sabe que hay vacunas como la del dengue que ha producido estos problemas. Y se sabe, cuando se han ensayado contra el coronavirus o contra el virus inicial respiratorio que producen estos problemas. Por lo tanto, en el hemisferio norte el próximo otoño-invierno vamos a ver una ola epidémica muy superior con mayor gravedad y con mayor mortalidad. Estiman los expertos que entre el 20 y el 30% de los vacunados morirán. No queremos ser agoreros, pero realmente si se consigue alcanzar este 70% de vacunación que se quiere para el otoño alcanzamos lo que se llama un umbral de percolación o un umbral de epidemia porque los vacunados contagiarán también a los no vacunados y, por lo tanto se producirá una epidemia extensa y grave…”. Estamos hablando de que supuestamente se iba a producir una especie de pandemia zombie donde todos terminaríamos enfermando no ya por un virus inexistente sino por una proteínas voladoras asesinas que contagiaban, unas proteínas, por cierto que tenemos por todas partes en muchas de nuestras células y las células de los microbios, vida pluricelar y parasitos que nos componen. Ricardo, de la quinta columna, dijo esto en Octubre del 2021 en un programa externo donde por suerte había un periodista, justo por las fechas que la Dra Albarracin pronosticaba que moriría el 30% de la población vacunada: “…Hoy publicaba el Reino Unido que el 80% de las personas que habían sido vacunadas ya han fallecido. Y cómo fallecen. Porque no lo hacen de forma instantánea.” Afortunadamente el periodista con el que estaba conversando le pregunta esto: “¿Cómo qué el 80% de las personas que han sido vacunadas han fallecido?” Respondiendo Ricardo: “Con la pauta completa, efectivamente.” Contestandole de forma ironica el periodista: “Entonces, habría muerto prácticamente medio Reino Unido.” Termina Ricardo diciendo: “Bueno, medio Reino Unido si las cifras son correctas, al menos, eso lo publica The Daily Expose.” El periodista le insiste en que debe ser un error: “Pero bueno, eso, lógicamente esa noticia hay que ponerla entre comillas, porque, lógicamente eso no ha sucedido, no.” No estamos hablando de unos cuantos cientos o miles de muertos, el 80% de la población vacunada de Reino Unido son millones de personas. He de decir que luego Ricardo reconoció este error. Realmente daba igual ya que se había dedicado y se dedica a introducir el miedo en todas las personas que se han vacunado contándoles una historia de terror, donde el grafeno y el 5G se dan la mano. Nosotros no hemos creído en la existencia de un virus que provocase el Covid como no creemos en la existencia de ningún virus, y por tanto es imposible que algo que no existe cree una pandemia. Si que creemos en la existencia de la posibilidad de estar siendo envenenados con todo tipo de sustancias salvo la que estuvo en boca de todos, el grafeno. Ya saben, esos grupos de carbono que crean estructuras moleculares en forme de hexágono de las que el supuesto Dr Andreas Noack decía que formaban cuchillas de hidróxido de grafeno que circulaban por nuestro sistema circulatorio cortándolo desde dentro. Todas nuestras células tienen estructuras que acaban en átomos y muchas moléculas como por ejemplo los colorantes adoptan formas en forma de cuchilla…y no, no nos cortan por dentro, aunque como yo he contado en mas de una ocasión incluso se pueden quedar atrapadas en las estructuras que replican el ADN dentro de nuestras células…es muy difícil pero no imposible. "Grafeno (átomos de carbono, nuestra materia misma) que se comporta como cuchillas de afeitar." "Trozos de proteínas que se pueden contagiar." "Proteínas que utilizamos en infinidad de sistemas dentro de nuestro cuerpo que nos pueden enfermar." No, no creo que eso sea ciencia. Asi es como se las gasta la “reliciencia” mezcla entre religión y ciencia que impone el poder global. Desde luego la misteriosa desaparición del supuesto Dr Andreas Noack, del que no hay datos que corroboren que sea científico, ocultan las verdaderas brutalidades del sistema como la ocurrida al cardiólogo suizo Dr. Thomas Binder. Este fue internado en un psiquiátrico por decir la verdad sobre el Covid19. Como condición para su puesta en libertad, le obligaron a tomar una medicación psiquiátrica. Esto no es la primera vez que ocurre. Jane Burgermeister, la periodista austriaca que destapó lo que ocurrió en el 2009 con la gripe porcina también fue ingresada en un psiquiátrico tras denunciar los planes de vacunación masiva de la gripe aviar en 2009. Jane Burgermeister es una periodista especializada en salud que ha trabajado para el British Medical Journal, Nature, The Scientist, Reuters, The Guardian y otros medios. En 2009, descubrió que la farmacéutica Baxter International había enviado material para vacunas contaminado con virus aviar vivo, sin atenuar, a 18 laboratorios en varios países europeos. En total, se trataba de 72 kilos de virus de la gripe mezclados con el mortal virus de la gripe aviar en sus instalaciones de nivel de bioseguridad BSL-3 en Austria. Esta contaminación fue detectada por el laboratorio checo BioTest al probar los viales con animales, que murieron pocas horas después. Este hallazgo llevó a Burgermeister a iniciar una investigación en la que recopiló numerosas evidencias y pruebas. Con esta información, presentó denuncias ante los tribunales contra diversas agencias e instituciones, como la OMS, la ONU, Baxter International, la FDA, el gobierno estadounidense y varios gobiernos europeos, así como contra banqueros, acusándolos de intento de genocidio y bioterrorismo mediante la vacunación contra la gripe. Finalmente, fue demandada, y un juez intentó declararla incapaz para poder enviarla a un psiquiátrico. Os voy a leer textual un trozo de uno de sus artículos de su ya desaparecido blog, para que podáis juzgar si estaba loca o no. En dicho texto nos habla de una entrevista que mantuvo con la unidad antiterrorista de Austria por sostener que una supuesta explosión inofensiva de un vial de gripe porcina en un tren en Lausana fue un acto deliberado. Dice así: “Cualquiera que piense que la idea de que la OMS y otros están liberando deliberadamente virus pandémicos es una teoría de la conspiración debería tener en cuenta que la unidad antiterrorista de Austria (BVT) me convocó para una entrevista de dos horas el 5 de julio de 2009 sobre los cargos que presenté sobre bioterrorismo del incidente en Suiza. La invitación de BVT decía Escuela internacional porque la entrevista fue principalmente sobre el incidente del tren y no sobre la contaminación de 72 kilos en Baxter de virus de la gripe con el mortal virus de la gripe aviar en sus instalaciones BSL3 en Austria. Aquí hay una copia de mis cargos del 1 de mayo de 2009 en alemán. Los profesionales tomaron en serio los cargos debido a los hechos, detalles del incidente que no pueden ser explicado a menos que asuma que fue un acto deliberado. Mis cargos alegan un incidente de bioterrorismo en Suiza el 29 de abril de 2009 cuando un contenedor "defectuosamente" lleno con viales de "gripe porcina", supuestamente directo de la Ciudad de México, y un laboratorio afiliado a la OMS, explotó en un tren Inter City abarrotado cerca de Lausana. Rociando a los pasajeros con el agente biológico mientras el contenedor era transportado a través de Suiza hasta el laboratorio nacional de gripe de Ginebra. El contenedor explotó con tanta fuerza que el técnico de laboratorio que lo transportaba y algunos de los pasajeros resultaron heridos. En el compartimento del tren había 61 personas expuestas al virus. Alegué que el contenedor herméticamente cerrado con hielo seco defectuoso era en realidad una bomba de cabon tipo "mochila" diseñada para evadir los detectores electrónicos en el aeropuerto y la estación de Zurich, y para explotar en un momento específico en los compartimentos climatizados del tren: un espacio relativamente cerrado con temperatura constante, etc. un ambiente ideal para esparcir un agente aerolizado por la fuerza de la explosión. El contenedor tenía 3 capas. La parte más interna contenía un frasco de gripe porcina. La segunda capa contenía hielo seco. La tercera capa era de sellado hermético. Cuando el hielo seco o el CO2 sólido se derrite, se convierte en gas. A medida que el hielo seco de la segunda capa del contenedor se derritió en el tren, el volumen de gas de la segunda capa aumentó y, por tanto, la presión sobre el vial. La detonación del contenedor se debió a la creciente presión del hielo seco que se evaporaba tanto en el vial en la parte más interna como en el contenedor más externo. De hecho, el hielo seco sirvió como detonador. El hielo seco se sublima. Cambia directamente de sólido a gas. Por lo tanto, los paquetes y sobreenvases no deben cerrarse herméticamente. Deben permitir que los gases escapen para evitar la acumulación de presión. • A medida que el hielo seco se sublima, crea gas dióxido de carbono, que es incoloro e inodoro. La idea de que un laboratorio pueda haber colocado accidentalmente hielo seco dentro del contenedor en lugar de afuera es increíble, simplemente. Tan increíble como tomar un tren Inter City para transportar muestras de virus consideradas lo suficientemente peligrosas como para causar una emergencia global, sin avisar a las autoridades ferroviarias suizas. Sostengo que se eligió el compartimento con aire acondicionado del tren Inter City porque, al igual que el interior de un avión, ofrece condiciones óptimas para el bioterrorismo ya que actúa en la medida en que la temperatura y las corrientes de aire permanecen bastante constantes, lo que permite cálculos más precisos. La explosión se produjo a las 18.39 en Friburgo y el tren fue detenido. Además, en primer lugar, los viales de gripe pandémica nunca deberían haber sido transportados en un tren de pasajeros, una clara violación de la ley. Los pasajeros pudieron regresar a sus casas sin ningún control médico gracias a la intervención de un funcionario del laboratorio nacional. En el momento de la explosión no se había registrado ni un solo caso de gripe "porcina" en Suiza. Mientras tanto, la gripe se está propagando lenta pero seguramente, lo que ayuda a la OMS a justificar su declaración de nivel 6 de pandemia. Los informes de Flutrackers muestran que la mayor incidencia de gripe "porcina" en Suiza se encuentra en el cantón de Vaud, Lausana, lugar del incidente del tren de la "gripe porcina". Una persona ha sido infectada dentro de Suiza; no está claro cómo pudo ocurrir. ¿Podría esa persona haber sido un pasajero en ese tren? Los principales medios de comunicación se apresuraron a descartar el incidente, diciendo que el virus de la gripe porcina era inofensivo. Pero si era tan inofensivo, ¿por qué la OMS alegaba una emergencia epidémica mundial?” Lo ultimo que sabemos de Jane es que tuvo que refugiarse en Grecia y borrar los dos blogs que tenia. Les he contado la historia de la periodista austriaca para que comprendan que, aunque trabajemos con buenas intenciones, nuestro trabajo puede ser usado para generar miedo, como ha sucedido en otros casos. Nosotros no creemos en la existencia de virus asesinos, sino en estructuras que transmiten información, como señala el científico Máximo Sandín. La ciencia oficial está descubriendo, por ejemplo, que dentro de ese 80% del ADN que anteriormente se consideraba "basura", hay cientos de virus... y esto ocurre en cada una de nuestras células. Así que hoy lucharemos contra los enemigos que vemos y los que no vemos, poniéndole el cascabel al gato. Ponerle el cascabel al gato puede significar enfrentarse a situaciones incómodas, resolver conflictos difíciles, tomar decisiones impopulares o enfrentar riesgos personales en nombre de un objetivo mayor. Informarnos e informar a otros de la llegada de un peligro o de la conveniencia o no de cierta decisión sirve para adelantarnos al golpe de ese enemigo o impedir ser dirigidos en la dirección que éste busca. Por eso los médicos debéis ser sinceros. La sinceridad es el pilar que sostiene la transparencia y la confianza en una sociedad. En un mundo cada vez más amenazado por la manipulación y el control, la verdad se convierte en nuestro único escudo contra la distopía. Al aferrarnos a la sinceridad, evitamos caer en la trampa de las ilusiones y los engaños que alimentan un futuro oscuro. Así, la honestidad no solo nos libera, sino que también actúa como la brújula que nos guía hacia un mundo más justo y humano. ………………………………………………………………………………………. Thomas Binder, Peter McCullough, Dr. Dean patterson, Dr. Vernon Coleman, Dr. Rich McCormick, doctora Kerryn Phelps, Dr Joseph Ladapo, Dra. Simone Gold, Leonardo González Bayona, Dr. Rashid Buttar. ………………………………………………………………………………………. Invitados: …. Dra Yane #JusticiaParaUTP @ayec98_2 Médico y Buscadora de la verdad. Con Dios siempre! No permito q me dividan c/izq -derecha, raza, religión ni nada de la Creación. https://youtu.be/TXEEZUYd4c0 …. UTP Ramón Valero @tecn_preocupado Un técnico Preocupado un FP2 IVOOX UTP http://cutt.ly/dzhhGrf BLOG http://cutt.ly/dzhh2LX Ayúdame desde mi Crowfunding aquí https://cutt.ly/W0DsPVq ………………………………………………………………………………………. Enlaces citados en el podcast: La libertad de ayudar: programa de ayuda a Manuel Jesús Rodríguez https://www.youtube.com/live/PZs5N_3OShk Dra. Nadiya Popel en Olot (16 Febrero 2024) https://www.ivoox.com/dra-nadiya-popel-olot-16-febrero-2024-audios-mp3_rf_124428201_1.html Nadiya Popel: La seguridad social va a colapsar en junio del 2024. https://www.ivoox.com/nadiya-popel-la-seguridad-social-va-a-colapsar-audios-mp3_rf_121285631_1.html Retratos de una historia NO contada: Ozonoterapia https://www.ivoox.com/retratos-historia-no-contada-ozonoterapia-audios-mp3_rf_122257080_1.html POR FIN PEDRO SÁNCHEZ HACE CASO AL BIÓLOGO : YA LO DIJE HACE CINCO MESES https://www.youtube.com/watch?v=VelFbxSc4v8 El biólogo Fernando López-Mirones: "España no terminará con el Covid19 hasta después del verano” https://www.youtube.com/watch?v=SpFWcbu2Tac Web del Dr Vernon Coleman https://vernoncoleman.com/ Desinformantes. Una herramienta contra los voceros de la mentira en la pandemia https://saludconlupa.com/series/desinformantes/ 30% mortandad pronosticado por la Dra Albarracin https://x.com/tecn_preocupado/status/1458902173589323776 La Dra Albarracín y otros expertos predicen un aumento impresionante de la mortandad entre personas vacunadas para este otoño https://x.com/tecn_preocupado/status/1383714700362326018 FLASHBACK A 2009 Y MI ENTREVISTA DE 2 HORAS CON LA UNIDAD ANTITERRORISTA DE AUSTRIA SOBRE EL ACTO DE BIOTERRORISMO DE LA OMS EN SUIZA https://web.archive.org/web/20210126013729/https://thefourthempire.blogspot.com/2020/02/flashback-to-2009-and-my-2-hour.html Un contenedor de virus explota en un tren interurbano https://web.archive.org/web/20091225054307/http://www.20min.ch/news/dossier/schweinegrippe/story/16556954 Contenedor con virus de la gripe explota en un tren https://web.archive.org/web/20090501124053/http://www.welt.de/wissenschaft/article3639195/Behaelter-mit-Grippeviren-im-Zug-explodiert.html Cuenta suspendida de Jane Burgermeister en Twitter https://x.com/constanzag77/status/1734239222905905400 Tejiendo la red de la vida (web de Maximo Sandin) https://somosbacteriasyvirus.com/ ………………………………………………………………………………………. Música utilizada en este podcast: Tema inicial Heros Carlos Rivera - Sincerándome https://www.youtube.com/watch?v=JCZQXXrDEBc Gustavo Cordera - ¿Cómo Enfrentar el Miedo? https://youtu.be/uZjBYFB9DBE?feature=shared Kaos Urbano - Imperdonable https://youtu.be/j8Gm5hpB_dE?feature=shared Los Chikos del Maíz - Esta Ciudad Es de Mentira https://www.youtube.com/watch?v=iIb4LLemkQ0 ………………………………………………………………………………………. Epílogo BUSCANDO LA VERDAD - RICKY CAMPANELLI & JIMMY BOSCH https://www.youtube.com/watch?v=uGXnpk4JUGk
In this episode of The New CISO, guest Chris Fredrick, Deputy CISO at Baxter International, returns for the final part of his interview series with host Steve.In parts one and two, Chris shared his background and the lessons he's learned during a breach. Today, Chris joins host Steve to discuss maintaining a productive outlook while looking for a new position. Listen to the episode to learn more about the lessons you can learn at every role, the importance of perception, and job-hunting challenges.Listen to Steve and Chris discuss the best time to leave a position post-breach and how to stay positive in the face of rejection:A New Job (1:40)After working on the SOC with Steve, Chris felt ready for a new challenge. He then saw a role that scared him, making him believe that that was the right position. This decision set him down his CISO path.However, this new position was temporary because when he threw his hat in the ring for the permanent role, it didn't work out. Ultimately, this rejection caused Chris to reflect on his career journey.Doing Things Differently (6:03)Steve asks Chris if he would have done things differently in his interview, knowing what he knows now. Chris would make the same decisions, especially since his time there had many challenges. Even though that role didn't pan out, Chris learned a lot during this time. He built confidence in his presentation skills and had the opportunity to meet more established CISOs. By networking with other CISOs, Chris realized he truly belonged in the security world.The Value of Stoicism (10:05)Chris advises on how to handle job rejection. He refers to Stoicism, which states we cannot control the outcome but can control our perception.When bad things happen, we can perceive it as a positive that will set us on the right path.Looking For Work (15:35)Despite Chris' impressive career history, it took him months to find his next role. After evaluating his many interviews, Chris recommends that security recruiters learn more about the field to better choose candidates. Chris and Steve then discuss the other lessons Chris learned during the job-hunting process, including what questions interviewers should or shouldn't ask. Referring to Stoicism again, Chris also recommends structuring a routine around job hunting, including doing a positive hobby you enjoy.The New CISO (28:32)To Chris, being a new CISO means understanding that we are tasked with the impossible. Therefore, it's essential to build an environment where people never feel like they are being asked to do the impossible for the ungrateful.Links:Linkedin
In this episode of The New CISO, guest Chris Fredrick, Deputy CISO at Baxter International, returns for the second part of his interview series with host Steve.In part one, Chris shared his background and the beginning of his professional journey. Today, Chris joins host Steve to discuss a pivotal moment in their careers: a significant breach. Listen to the episode to learn more about how Chris transitioned into a managerial role and stepped up during a crisis.Listen to Steve and Chris discuss who managers really work for and the mark of a great leader:Welcome Back, Chris (1:52)Steve and Chris discuss where they left off in the last episode when they left their security team for a new opportunity.Focusing on insider threats, Chris shares his daily work for this specific role. During this time, Chris focused less on operations and built a program instead. He also researched what would be in an insider program.Vulnerability Management (4:10)Chris reflects on the lessons he learned while doing vulnerability management that made him the leader he is today. Chris believes this time taught him how to tell a good story and have clear metrics to back himself up.Network Security (9:28)After working in vulnerability management, Chris moved into network security with Steve and created a Soc. Chris initially came in as an individual contributor until he became a team lead before eventually becoming the manager.When he was a manager, Chris realized his role now was to worry about his team and less about himself. It was a profound moment for Chris when he discovered this truth.The Breach Itself (15:14)Chris shares what lessons he learned from a significant security breach. Chris and his team noticed for a while that there were warning signs of the breach but were initially ignored.However, when the event happened, they could take what they knew and move forward. Because Chris had working partnerships with other teams, he was able to get the help they needed, showcasing the importance of building your relationships before a crisis.Client Management (20:48)Steve presses Chris on what he remembers regarding the client management side of this time. Chris recalls dealing with many calls from clients who were understandably concerned. Many of these calls became heated, but one client assured Chris he understood what he was going through. As a result, Chris tries to be empathetic with others since they could be having a bad day, which could affect their behavior.Pride In Their Team (28:25)Steve reflects on how working with this incredible team was one of the best memories of his career. He has immense pride in this group, which Chris shares.Chris loved building something from nothing and seeing the great things their colleagues have done since. Forming a great team requires a healthy culture that brings people together.Stepping Up (31:38)After Steve left, Chris had to step up into a higher leadership role. This change became a pivotal moment in Chris's career, coinciding with the birth of his first child.Links:Linkedin
In this episode of The New CISO, Steve is kicking off the first part of a three-part series with guest Chris Frederick, Deputy CISO at Baxter International.Chris began his career as a technician and met Steve on a small security team managing a large network. Now, Chris joins today to share key lessons from his early career and set the stage for the next upcoming episodes. Listen to the episode to learn more about Steve and Chris' time working together, the process of changing companies, and learning to be a better leader.Listen to Steve and Chris discuss how to deliver the news you're leaving a company and how managers should accept said news:Meet Chris (1:46)Chris has worked in IT security for over twenty years and knew since college that this area of the industry was his passion. Since starting a leadership role, he has found his new calling: becoming the best leader he can be.Infosec Memory Lane (5:04)Chris shares the memories of his time working with Steve on their small infosec security team. Chris remembers feeling overwhelmed initially but learned to handle the scope of his many responsibilities. Steve and Chris reminisce about the positives of this experience and the challenges. The best part was the camaraderie they felt as a team.Lessons Learned (9:43)Steve presses Chris on the lessons he learned during their time on the infosec team. This experience taught Chris the importance of curiosity and building credibility.Another valuable lesson was learning to have respectful conversations when colleagues disagree.Changing Companies (18:23)While working together, Steve and Chris had the opportunity to change companies after their CISO left. Chris walks through what occurred and the communication lessons it taught him. He wishes he had done some things differently since multiple people leaving put his manager in a tough spot, but he also learned valuable leadership skills.Links:Linkedin
In this episode of the Thoughtful Entrepreneur, your host Josh Elledge speaks to the CEO & Founder of InCommon, Dan Michelson.Dan's extensive experience in building and growing companies, particularly in the healthcare sector, has given him unique insights into the importance of culture in fostering growth and creating a positive work environment.The onset of COVID-19 has brought about significant challenges and changes in how people work. Intrigued by these changes, Dan embarked on an extensive research project, interviewing 1,700 CEOs across various industries and countries. His goal was to understand how companies were approaching the future of work in this new reality.What he discovered was a fundamental shift in the way work is approached. Things are moving from a traditional workflow to a more integrated life flow. Work is no longer defined by a specific time and place, but has become more of an individual experience rather than a collective one.Dan firmly believes there are better solutions than forcing employees back to the office to improve company culture and productivity. Instead, he advocates for a flexible approach that suits each company's unique needs. In his book, "Holy Shift," Dan explores the mindset and strategies needed to navigate these changes and create a successful work environment.Dan's company, InCommon, focuses on automating and simplifying the concepts of community, opportunity, relationships, and experiences that correlate with employee engagement, retention, and productivity. They work with companies to understand their unique needs and help them navigate the future of work in a way that benefits both the company and its employees.Key Points from the Episode:Importance of using culture to grow companies and create a positive work environmentShift in the way work is approached, from traditional workflow to integrated life flowFlexible approach to improve company culture and productivityDifferent needs and challenges of remote work and distributed teamsExamples of technology companies and manufacturing/service-based settingsHistorical precedents of how employers have adapted to similar situations in the pastImpact of pandemics on work and labor movementsInCommon's focus on automating and simplifying concepts related to employee engagement, retention, and productivityWorking with companies to improve community, opportunity, relationships, and experiencesAbout Dan Michelson:Dan Michelson is the Founder and Chief Executive Officer of InCommon, a software and services company dedicated to fostering inclusive workplace cultures. He previously held key roles at Allscripts, where he served as Chief Strategy Officer and Chief Marketing Officer, contributing significantly to the company's growth from 100 to over 6,000 employees and $1 billion in annual revenue. With extensive experience in healthcare technology, Dan provided consulting for leading hospitals and health systems. He has also worked with companies like Baxter International and AstraZeneca. Dan is actively involved in education, serving as an Adjunct Professor at Loyola University in Chicago, teaching Decision Strategy. He holds a BS in Finance from Indiana University and an MBA from DePaul University. In addition to his professional pursuits, Dan is a philanthropist, founding projectMUSIC™, a charity concert initiative, and HackHunger™, a collaboration aiming to combat hunger...
Shares of medical device makers like Davita and Baxter International plunged after Novo Nordisk said its GLP-1 drug Ozempic had some positive results in trials against kidney failure. So what could the impact be of a potential do-it-all drug? We surround the trade with Dr. Kavita Patel and Mizuho's Jared Holz. Fast Money Disclaimer
Steve Grzanich has the business news of the day with the Wintrust Business Minute. Deerfield’s Baxter International has taken its headquarters campus off the market and will hold onto the property and reinvest in the location. The decision ends a months-long controversy to develop an industrial park on the 101-acre property. Crain’s reports Baxter wants […]
We are excited to bring you this episode of the MedTech Mentor Podcast, welcome Nicholas Trpezanovski, Founder of NJT MedTech Solutions NJT MedTech Solutions is an upcoming medtech consultancy supporting start-ups and small and medium medtech businesses to grow and prosper This episode was recorded back when Nicholas had just founded NJT MedTech Solutions in mid 2022. Prior, Nicholas had a remarkable track record as Lead of Corporate Accounts, Government Affairs and Distribution for Baxter International, Head of Corporate Accounts and Government Affairs at Hillrom and held several senior positions at Synthes and Johnson & Johnson. Nicholas's incredible journey takes us from his roots as a nuclear medicine scientist to founding his own medtech consultancy - a testament to his drive and determination Nicholas inspires us to approach our career not as a rigid upwards ladder but as a flexible lattice, encouraging us to break free from our comfort zones and explore new horizons. Don't underestimate the power of that first step - even a casual coffee chat can lead to life-altering opportunities. With a wealth of experience from the medtech industry, Nicholas offers invaluable advice on the importance of building personal connections throughout your extended social network. Nicholas is a treasure trove of knowledge, generously sharing his wealth of insights. He is a cherished member of the MedTech Mentor Village, and we are confident that you will find his conversation as enlightening and enjoyable as we did. Keep an eye out for Part II on Nicholas's reflections 1 year later Links mentioned in this episode: https://njtmedtech.com.au/ This podcast is hosted by ZenCast.fm
Say It Skillfully® is a show that helps you to benefit from Molly Tschang's expert guidance on the best possible ways to speak your mind at work in a positive and productive manner. Episode 195 is another edition of “Top Talks from the Top”. Do yourself a big favor and take in the many, many gems that Harry Kraemer generously shares, not least of which is tapping into the power of self-reflection. Over a 23-year career at Baxter International, he went from finance whiz literally to Chairman & CEO. The eldest of 5, Harry recalls moving every few years as his dad was a salesman and growing up “fairly religious.” His Uncle Francis was a priest, which was his first career choice (that didn't exactly manifest). Harry shares the pivotal moment with his to-be father-in-law that set him on a trajectory he'd never imagined! Young Harry learned how silence can be a pretty good thing, such that for the past 4+ decades, he self-reflects for 15 minutes every single day. It's made all the difference as he doesn't suffer from “worry, fear, anxiety, pressure, and stress!” Harry talks openly about how to be when things are going well, AND to consider the inevitability of when things go downhill. He's all about “no surprises”. He walks the walk of truly valuing people and relationships and recollects fondly the opportunity to be constantly meeting people and learning from them in the 140 countries Baxter operated in. I've never known anyone to thrive as much in relating human to human! Don't be surprised how Harry's people focus contributed to his ascent at Baxter (something he NEVER envisioned). And his values-based leadership made any “tough talks” less so! Hear how he embraced his privilege and responsibility to set an example of what a good person to his 55,000 team members. You'll be better for tuning into this refreshing conversation. Harry inspires us all to know no boundaries and to commit to taking action so that all can be safe, seen and heard, and our true and very best selves! And no time like the present to amp up your leadership communications, a core component to Harry's sustained success in all his endeavors. Don't miss taking Molly's 1st LinkedIn Learning course, “Leadership Communication in the Flow of Work.” Here's a link for free 24-hr access https://www.linkedin.com/posts/mollytschang_sayitskillfully-communicationskills-passion-activity-7099873982077657088-L-qC?utm_source=share&utm_medium=member_desktop Hope it helps you lead to your full potential. Happy learning!
Say It Skillfully® is a show that helps you to benefit from Molly Tschang's expert guidance on the best possible ways to speak your mind at work in a positive and productive manner. Episode 195 is another edition of “Top Talks from the Top”. Do yourself a big favor and take in the many, many gems that Harry Kraemer generously shares, not least of which is tapping into the power of self-reflection. Over a 23-year career at Baxter International, he went from finance whiz literally to Chairman & CEO. The eldest of 5, Harry recalls moving every few years as his dad was a salesman and growing up “fairly religious.” His Uncle Francis was a priest, which was his first career choice (that didn't exactly manifest). Harry shares the pivotal moment with his to-be father-in-law that set him on a trajectory he'd never imagined! Young Harry learned how silence can be a pretty good thing, such that for the past 4+ decades, he self-reflects for 15 minutes every single day. It's made all the difference as he doesn't suffer from “worry, fear, anxiety, pressure, and stress!” Harry talks openly about how to be when things are going well, AND to consider the inevitability of when things go downhill. He's all about “no surprises”. He walks the walk of truly valuing people and relationships and recollects fondly the opportunity to be constantly meeting people and learning from them in the 140 countries Baxter operated in. I've never known anyone to thrive as much in relating human to human! Don't be surprised how Harry's people focus contributed to his ascent at Baxter (something he NEVER envisioned). And his values-based leadership made any “tough talks” less so! Hear how he embraced his privilege and responsibility to set an example of what a good person to his 55,000 team members. You'll be better for tuning into this refreshing conversation. Harry inspires us all to know no boundaries and to commit to taking action so that all can be safe, seen and heard, and our true and very best selves! And no time like the present to amp up your leadership communications, a core component to Harry's sustained success in all his endeavors. Don't miss taking Molly's 1st LinkedIn Learning course, “Leadership Communication in the Flow of Work.” Here's a link for free 24-hr access https://www.linkedin.com/posts/mollytschang_sayitskillfully-communicationskills-passion-activity-7099873982077657088-L-qC?utm_source=share&utm_medium=member_desktop Hope it helps you lead to your full potential. Happy learning!
On this episode of This Thing Called Life Podcast, host Andi Johnson is going to talk to Shelly Sherman and Stephanie Jackson. They are discussing kidney health and an exciting new project that is being launched to shed light on kidney disease as well as prevention. No doctor or medical expert will kill you for your organs; In fact, no medical professional is aware of your donor status until your death is declared. Tune in for more information! Episode Highlights: Host Andi Johnson has a few big asks. Will you join us and be a part of this interconnected life sustaining community by registering to be an organ, eye, and tissue donor? Will you make the commitment to become more educated about living donation and championing the donation cause? Shelly is associated with the Cincinnati, Ohito chapter of The Links, Incorporated and she served as the Health and Human Services Facet Committee chair. The Ohio central chapter was granted an award by Baxter International for increasing the awareness of kidney health in the communities in which Shelly lives and primarily in the African American community. What is GFR? Shelly has been working hard in the community to make sure people know where they are regarding their GFR, which lets them know how well their kidneys are functioning and what they can do to maintain kidney health. The Links organization was founded in 1946 on the premise of friendship, and Shelly wants to uplift and elevate people by providing health information. Stephanie and Shelly first met through collaboration with The Center For Closing the Health Gap. Shelly had goals in mind based on the grant they received regarding the number of people that they needed to touch and the number of community partnerships that they needed to do. Shelly and Stephaine share the experiences they have had with training sessions and connecting in the community. They hope people will continue to listen to the podcast and continue doing some things and spreading the word in their communities. When people are ill, you can see it on their skin and eyes. You can notice the effects of kidney and liver illness on the skin and other body systems. Garlic is great for decreasing inflammation; It has Vitamin C, Vitamin B6, and Manganese, a great alternative for your seasoning. If you want to decrease your psyllium, you can add more garlic, which is great for your heart and your kidney. The one thing is to avoid canned and packaged chicken breast because those can contain sodium and other preservatives. Raising awareness and making small changes goes such a long way in promoting healthier lifestyles. There is a great ripple effect too when you share information like this with those in your family and circles. 3 Key Points: Blueberries are an important food for kidney patients. They serve as antioxidants and are very good for healing. In addition, they help your body to increase urination. People talk about dialysis and transplant, and these are things that you want to avoid. By opting for a healthier lifestyle and changes in the food you eat, you can do that. There are so many ways you can just move your body, and Stephanie always tells people 15 to 20 minutes is sufficient. Make sure that your body is doing something that it doesn't do every day. Tweetable Quotes: “Whatever we are putting in our body, the body is going to use, and if we don't put in things that our body can use, then our body is not going to be able to function the way it's supposed to.” – Stephaine “Your body does need fat but only healthy fats because it helps everything stay lubricated and work well in all facets.” – Stephaine “So much of what happens to us is preventable, and a lot of it is due to a lack of information that is sometimes missed in our community.” – Shelly “Sometimes, we do have a mistrust of the medical systems, and we don't get some of the information that we need to have, but we can share it and start to educate each other.” - Shelly Resources Mentioned: LifeCenter | Website | Facebook | Instagram | YouTube| Twitter Andi Johnson website |LinkedIn Organ Donation Website https://www.cincinnatilinks.org/black-kare-initiative https://www.facebook.com/CincinnatiLinks https://www.instagram.com/cincinnatilinks/ https://www.yoursweetestlife.com/ https://www.facebook.com/yoursweetestlifewithstephaniej https://www.instagram.com/yoursweetestlifewithstephaniej/
US futures are indicating a positive open after finishing higher in Monday trade. European equity markets have opened firmer, following broad strength in Asia. Focus remains on banking sector turmoil. US is studying ways to guarantee all deposits without Congressional approval if situation worsens. Market is digesting implications for monetary policy. Strategists flag concerns about harder economic landing, driven by pullback in lending amid tightening of financial conditions. Wednesday's Fed meeting is consequential, with markets pricing in a 25bp rate hike. Companies Mentioned: UBS, Credit Suisse, First Republic Bank, Baxter International
09 March 2023: Helen is coming live from the new NH Collection Dubai on The Palm where she catches up with the Marketing Manager to find out more about the hotel Scott Armstrong is sharing the silent struggles of men Dr. Ayman Karkar explains how we can keep our kidney in top shape on World Kidney Day We find our how AI is helping the next generation Reece Baker shares his incredible weight loss journey And Christina Ioannidis is educating women who are struggling through menopause.See omnystudio.com/listener for privacy information.
Steve Grzanich has the business news of the day with the Wintrust Business Minute. Deerfield-based Baxter International is the latest Chicago-area company to announce job cuts. It plans to reduce its global headcount by less than 5%. The cuts come as the company launches a restructuring plan. As many as 3,000 employees will be cut […]
Harel Shachar was born and raised in Israel and started his academic journey studying Biotechnology Engineering after three years of army combat service. He completed an internship program at John Hopkins University and graduated with honours. Harel returned to Isreal to start a career in Life Sciences at Protalix Biotherapeutics. However, he soon realized that his natural abilities were underutilized and decided to pursue an MBA while working in the Health Care division of 3M. He eventually moved his family to Canada in 2014 and has worked at FroggaBio and Baxter International in several sales, product and marketing roles. In this episode, we'll discuss Harel's immigration journey to Canada and his recommendations for success in the MedTech industry.
Steve Grzanich has the business news of the day with the Wintrust Business Minute. Baxter International will restructure the company with a spin-off of one of its divisions and the resignation of a top executive. The Deerfield-based medical products company is spinning off its kidney care business into a separate publicly trading company. That move […]
The Winning ESG Companies articles include: “11 Best ESG Dividend Stocks to Buy According to Al Gore”; “Top 12 ESG Companies in 2022”; “IBD's 100 Best ESG Companies For 2022”; “Investing in green energy here are the top 5 stock picks”; “Capital Keeps Flowing Into Green Bonds Despite Inflation Challenges”; and much more this episode… Podcast: The Winning ESG Companies Transcript & Links, Episode 93, November 4, 2022 Hello, Ron Robins here. Welcome to my podcast episode 93 published on November 4, 2022, titled “The Winning ESG Companies” — and presented by Investing for the Soul. Investingforthesoul.com is your site for vital global ethical and sustainable investing mentoring, news, commentary, information, and resources. Remember that you can find a full transcript, and links to content – including stock symbols and bonus material – on this episode's podcast page located at investingforthesoul.com/podcasts. Now if any terms are unfamiliar to you, simply Google them. Also, a reminder. I do not evaluate any of the stocks or funds mentioned in these podcasts, nor do I receive any compensation from anyone covered in these podcasts. Furthermore, I will reveal to you any personal investments I have in the investments mentioned herein. Additionally, quotes about individual companies are brief so that I can get as many companies covered as possible in the time allowed. Please go to this podcast's webpage for links to the actual articles where you'll find much more great company information. ------------------------------------------------------------- 1) The Winning ESG Companies Now the content of this first article will likely interest most of you. It's titled 11 Best ESG Dividend Stocks to Buy According to Al Gore and found on yahoo.com. It's by Vardah Gill. Al Gore is a former U.S. Vice President, Nobel Peace Prize winner, and well-known for his environmental advocacy and investment management skills. He co-founded Generation Investment Management. Here's some of what Mr. Gill has to say. Incidentally, quoted dividend yields are as of October 28. “For this list, we selected stocks from Generation Investment Management's 13 F portfolio as of Q2 2022… Moreover, these companies pay dividends to shareholders. The stocks are ranked according to their stake values in the hedge fund's portfolio. 11. Microchip Technology Incorporated (NASDAQ:MCHP) Generation Investment Management's (G-I-M's) Stake Value: $76,630,000 Microchip Technology Incorporated is an Arizona-based manufacturing company that specializes in microcontrollers, mixed-signal, and other related circuits… It currently pays a quarterly dividend of $0.301 per share and has a dividend yield of 1.94%. 10. The Cooper Companies, Inc. (NYSE:COO) GIM's Stake Value: $394,222,000 The Cooper Companies currently pays a quarterly dividend of $0.015 per share, with a dividend yield of 0.02%. 9. Carlisle Companies Incorporated (NYSE:CSL) GIM's Stake Value: $408,039,000 Carlisle Companies Incorporated is an Arizona-based manufacturing company that specializes in a wide range of products including optical fibers and defense electronics… it pays a quarterly dividend of $0.75 per share and has a dividend yield of 1.24%. 8. Thermo Fisher Scientific Inc. (NYSE:TMO) GIM's Stake Value: $486,718,000 Thermo Fisher Scientific is an American supplier of scientific instruments, reagents, and other software products… It currently pays a quarterly dividend of $0.30 per share with a dividend yield of 0.24%. 7. Intel Corporation (NASDAQ:INTC) GIM's Stake Value: $552,560,000 Intel Corporation is an American multinational semiconductor company that also specializes in cloud computing and data centers…. It currently pays a quarterly dividend of $0.365 per share and has a dividend yield of 5.19%. 6. Applied Materials, Inc. (NASDAQ:AMAT) GIM's Stake Value: $555,224,000 Applied Materials is a California-based manufacturing company that supplies services and software for the manufacturing of semiconductor chips… The stock has a dividend yield of 1.19%. 5. Analog Devices, Inc. (NASDAQ:ADI) GIM's Stake Value: $649,049,000 Analog Devices is an American semiconductor manufacturing company that specializes in data conversion, signal processing, and power management technology… (It has) a quarterly dividend of $0.76 per share and… a dividend yield of 2.13%. 4. Becton, Dickinson and Company (NYSE:BDX) GIM's Stake Value: $789,414,000 Becton, Dickinson and Company is a New Jersey-based multinational medical device company… It pays a quarterly dividend of $0.87 per share, with a dividend yield of 1.49%. 3. The Charles Schwab Corporation (NYSE:SCHW) GIM's Stake Value: $800,177,000 The Charles Schwab Corporation is a Texas-based financial services company that offers investment and commercial banking services to its consumers… The stock has a dividend yield of 1.11%. 2. Baxter International Inc. (NYSE:BAX) GIM's Stake Value: $836,163,000 Baxter International is an American multinational healthcare company that specializes in kidney diseases and other chronic conditions… It currently pays a quarterly dividend of $0.29 per share and has a dividend yield of 2.09%. 1. Equifax Inc. (NYSE:EFX) GIM's Stake Value: $850,637,000 Equifax, a Georgia-based credit bureau company… Last year… announced that it will achieve net-zero greenhouse gas emissions by 2040… It currently pays a quarterly dividend of $0.39 per share and has a dividend yield of 0.94%.” End quotes. ------------------------------------------------------------- 2) The Winning ESG Companies This next article is also fascinating. You'll see in a moment. It's titled Top 12 ESG Companies in 2022 on yahoo.com. By Fahad Saleem. Here are some quotes from Mr. Saleem… “For this article we used the latest datasets of Just Capital a not-for-profit founded in 2013 by popular individuals like billionaire Paul Tudor Jones, Deepak Chopra, Rinaldo Brutoco, Arianna Huffington, Paul Scialla, Alan Fleischmann, among others. Just Capital ranks the largest US companies based on their performance related to issues concerning environment, workers, customers, communities and shareholders… We focused more on the environmental aspect of the ESG matrix of these companies… 12. Exelon Corporation (NASDAQ:EXC) Exelon Corporation is an Illinois-based utilities services company that owns nuclear, fossil, wind, hydroelectric, biomass, and solar generating facilities… claims to be the largest producer of zero-carbon electricity in the U.S. 11. PepsiCo, Inc. (NYSE:PEP) … in January last year announced that it plans to achieve net-zero greenhouse gas emissions across its supply chain by 2040. 10. Cisco Systems Inc. (NASDAQ:CSCO) In September last year, Cisco Systems Inc announced plans to reach net-zero emissions across all scopes by 2040. 9. Verizon Communications Inc. (NYSE:VZ) In 2019, it became the first US telecom company to issue a green bond. The offering raised about $1 billion in net proceeds. Verizon Communications has announced plans to generate renewable energy equivalent to 50% of its annual electricity consumption by 2025. 8. NVIDIA Corporation (NASDAQ:NVDA) The company says it's building a digital version of our planet on which it'll apply its AI and Omniverse technologies to predict weather changes and their effects over a span of several decades. NVIDIA Corporation GPUs will also be used to power the Department of Energy's supercomputer called ‘Kestrel' which is dedicated to advanced energy solutions. 7. Apple Inc. (NASDAQ:AAPL) … has an ambitious goal to become carbon neutral by 2030. 6. PayPal Holdings Inc. (NASDAQ:PYPL) Payments giant PayPal Holdings Inc announced last year that it plans to reach net-zero emissions by 2040. 5. Bank of America Corporation (NYSE:BAC) … has set a goal of achieving net zero greenhouse gas emissions by 2050. 4. Salesforce Inc. (NYSE:CRM) … announced in September 2021 that it achieved net-zero residual emissions across its full value chain and met its 100% renewable energy goal for its operations. 3. Microsoft Corporation (NASDAQ:MSFT) … plans to become carbon neutral by 2030… By 2050, Microsoft plans to remove the ‘historical emissions' it created since its founding. 2. Intel Corporation (NASDAQ:INTC) Earlier this year, Intel Corporation announced plans to achieve net-zero greenhouse gas emissions across its global operations by 2040. 1. Alphabet Inc. Class A (NASDAQ:GOOGL) … is the top ESG company in 2022, thanks to the billions of dollars' worth of ESG-related investments and ambitious goals it has set for the betterment of the environment. In its 2022 ESG report, the parent of Google said that it issued a whopping $5.75 billion in sustainability bonds, easily surpassing all peers in the industry.” End quotes. ------------------------------------------------------------- 3) The Winning ESG Companies Now to the first of our two company ranking lists. The reviewing article is titled IBD's 100 Best ESG Companies For 2022. It appears on investors.com and is by Kathleen Doler. Now some quotes from Ms. Doler. “Topping the list this year is Worthington Industries (WOR). J.B. Hunt Transport Services (JBHT) took second place. And rounding out the top three is data analytics provider Verisk Analytics (VRSK). All 100 companies on our 2022 list ranked in the top 15% of Dow Jones ESG scores and had an IBD Composite Rating of 81 or better (on a scale of 1 to 99), as of Aug. 31… Technology behemoths Texas Instruments (TXN) and Apple (AAPL) finished fourth and fifth respectively.” End quotes. ------------------------------------------------------------- 4) The Winning ESG Companies The second company ranking also has an intriguing background. It's called The Humankind 100 and this list is found on their site humankind.co. Here are some quotes from their site. “The Humankind 100 list is compiled annually by the research team at Humankind Investments, an investment manager whose mission is to invest in the manner that is best for humanity. You can learn more about the Humankind Value methodology by visiting our research or articles pages… Humankind 100 companies tend to contribute positively to humanity, for example by providing access to food, clean water, healthcare, or free digital services.” End quotes. Incidentally, though Humankind purports a unique methodology, they arrive at pretty much the same companies as most other 'best company ESG' lists. Nonetheless, they have an interesting concept that will appeal to many ethical and sustainable investors. Their top five companies are Alphabet, Inc. (GOOGL), Johnson & Johnson (JNJ), Pfizer Inc. (PFE), AbbVie Inc. (ABBV), and Verizon Communications Inc. (VZ). ------------------------------------------------------------- 5) The Winning ESG Companies Now back to a favorite sector with this article. It's titled Investing in green energy here are the top 5 stock picks on londonlovesbusiness.com. It's by LLB Finance Reporter. Here are some brief quotes with their picks. “With the green energy industry continually expanding, Maxim Manturov, Head of Investment Advice at Freedom Finance Europe, explores which companies are promising investment choices within the sector… (He chooses) Tesla (TSLA) Plug Power (PLUG) Enphase Energy (ENPH) Sunrun (RUN) First Solar (FSLR).” End quotes. ------------------------------------------------------------- Capital Keeps Flowing Into Green Bonds Despite Inflation Challenges Finally, we have this article titled Capital Keeps Flowing Into Green Bonds Despite Inflation Challenges by Ben Hernandez on etftrends.com. Here's some of what Mr. Hernandez says. “One option for fixed income investors looking for ESG bond exposure who also want the yield that corporate bonds can offer is the Vanguard ESG U.S. Corporate Bond ETF (VCEB). Additionally, the fund doesn't command a high premium with its low expense ratio of 0.12% and a 30-day SEC yield of 5.51%, as of October 17. (This bond fund) seeks to track the performance of the Bloomberg MSCI US Corporate SRI Select Index, which excludes bonds with maturities of one year or less and with less than $750 million outstanding, and it is screened for certain ESG criteria by the index provider, which is independent of Vanguard… The fund has a discerning screener. This adds an air of purity for VCEB's holdings, avoiding any greenwashing with a keen focus on environmental, social, and governance (ESG) initiatives. (It's) highlights: Provides debt issues screened for certain ESG criteria. Specifically excludes bonds of companies that the index sponsor determines are involved in and/or derive threshold amounts of revenue from certain activities or business segments related to adult entertainment, alcohol, gambling, tobacco, nuclear weapons, controversial weapons, conventional weapons, civilian firearms, nuclear power, genetically modified organisms, or thermal coal, oil, or gas. Excludes bonds of companies that, as determined by the index sponsor, do not meet certain standards defined by the index sponsor's ESG controversies assessment framework, as well as firms that fail to have at least one woman on their boards.” End quotes. ------------------------------------------------------------- One Other Honorable Mention Title: Top 5 Renewable Energy Stocks For Q4 2022 on forbes.com. By Q.ai. Canadian article Title: 10 Best ESG ETFs in Canada for Ethical Investing in (2022) - on savvynewcanadians.com. By Enoch Omololu. India article Title: Best ESG Funds in India: How Are They Different from Other Mutual Funds? On indmoney.com. ------------------------------------------------------------- Ending Comment Well, these are my top news stories with their stock and fund tips -- for this podcast: “The Winning ESG Companies.” Now, please be sure to click the like and subscribe buttons on Apple Podcasts, Google Podcasts, or wherever you download or listen to this podcast. That helps bring these podcasts to others like you. And please click the share buttons to share this podcast with your friends and family. Let's promote ethical and sustainable investing as a force for hope in these deeply troubled times! Contact me if you have any questions. Thank you for listening. Talk to you next on November 18th. Bye for now. © 2022 Ron Robins, Investing for the Soul
In this podcast, you will hear a panel discussion moderated by Dr Mahesh Chaubal, Baxter International, from the 2022 PODD Conference regarding opportunities to lower costs of development and manufacturing of drug delivery technologies through working with regulatory bodies, reformulating drugs to be more cost effective and analyzing the role of lifecycle management to reduce cost of goods. Panelists include: Ryan Doxey, KymanoxWenlei Jiang, FDA CDER/OGD/ORSRaymond Knox, Lyndra Therapeutics To learn more about the PODD Conference, please visit PODDConference.com.
What do ATI physical therapy, Athletico, and Ivy Rehab all have in common? They would not be here if not for the vision of NATA Hall of Famer, Dick Hoover and his idea for independent outpatient physical therapy clinics. Glen Snow shares the story of Physical Therapy Services, the first independent outpatient physical therapy clinic that went nation wide. In 1984 Glen was recruited by Dick to be the VP of business development. Glen helped open up 43 clinics and help grow the clinics to be worth 18 million dollars before they sold out to Baxter International in 1990. Their hard work paved the way for the current day independent outpatient physical therapy clinic. Glen is currently the President of Digijump and he and his wife Pam reside in Georgetown, IN.
Today we look back at a TownHall episode … Samuel Hill, Director Product Marketing at Medigate interviews Justin Heyl, Director, Enterprise Risk Management at Baxter International on advice for healthcare CISOs.
Strategies for protecting clinicians across the industry.Even before the COVID-19 pandemic, violence against clinicians was a pressing concern for the healthcare industry – with violence about four times more prevalent in healthcare than in any other industry. The pandemic has added new stressors and exacerbated those already present, leading to an uptick in workplace violence against clinicians across the country. Join host Mike Miliard as he talks to Jennifer Schmitz, president of the Emergency Nurses Association and chief nursing officer for Southern Maine Health Care, and Whitney Lloyd, VP of Customer Experience at Baxter International, about what strategies have worked for them in addressing workplace violence – and what digital tools have helped.
Meet Mike Mussallem:Mike Mussallem is the Chairman and CEO of Edwards Lifesciences. Prior to Edwards, he was at Baxter International. Currently, Mike serves on the board of the Advanced Medical Technology Association (AdvaMed) and is an advisory board member for the Leonard D. Schaeffer Center for Health Policy & Economics at the University of Southern California. He is a trustee of the University of California, Irvine Foundation and the Rose-Hulman Institute of Technology. Mike received a Bachelor's in Chemical Engineering from the Rose-Hulman Institute of Technology.Key Insights:For Mike Mussallem, Edwards Lifesciences has a responsibility to the patients they serve. That mission is baked into their technology, culture, supply chain, and strategy.Culture of Innovation. Mike emphasizes the importance of culture. Edwards, like many medical technology companies, wants a culture of innovation. To achieve that requires rewarding true innovation, not just increases in sales, as well as creating an environment where employees can admit failure and build off of it. (19:12)Supply Chain Resiliency. The pandemic had a limited impact on Edwards due to built-in redundancy. Edwards has multiple production plants and suppliers, with facilities around the globe that support their specific geographic area. Effective strategy combined with strong culture helped Edwards tremendously during the pandemic. (24:42)Culture Eats Strategy. Another fundamental aspect of Edwards' culture is its dedication to helping patients. The company brings that element to life through storytelling. Conferences or other events often showcase short films about how their technology directly impacts patients. When asked, 90% of Edwards employees think about patients each day when they make decisions. (29:36)Relevant Links:Learn more about Edwards LifesciencesRead “Edwards Lifesciences CEO Mike Mussallem on balancing innovation, ethics and resilience”
Anish Bafna , Chief Executive Officer & Managing Director , Healthium Medtech LimitedAnish leads with a vision to create access to precision Medtech for every patientglobally. His career spans 27 years with a strong focus on the Healthcare and devices sector,with stints in multiple countries. In his last assignment, he was President Rep inJapan, for Baxter International. He's also served as the RegionalHead- Emerging Asia at Baxter in Singapore, overseeing the operations of Indiaand South East Asia from 2015 to 2017.
May 10: Today on Townhall, https://www.linkedin.com/in/samueljhill/ (Samuel Hill), Director of Product Marketing at https://www.medigate.io/ (Medigate) interviews https://www.linkedin.com/in/jheyl/ (Justin Heyl), Director, Enterprise Risk Management for https://www.baxter.com/ (Baxter International) to discuss the challenge of closing the vulnerability reporting loop between Hospitals and Device Manufacturers. Healthcare systems know their threats. They know their vulnerabilities. And if they see something that needs to be changed or fixed, they want to be able to know what to do. How does Baxter approach the idea of vulnerabilities in the devices? How do they work with their customers to make sure that they have the right level of information? What advice would they give to a CISO looking at clinical devices?
On this episode of This Thing Called Life Podcast, host Andi Johnson is going to talk to Shelly Sherman and Stephanie Jackson. They are discussing kidney health and an exciting new project that is being launched to shed light on kidney disease as well as prevention. No doctor or medical expert will kill you for your organs; In fact, no medical professional is aware of your donor status until your death is declared. Tune in for more information! Episode Highlights: Host Andi Johnson has a few big asks. Will you join us and be a part of this interconnected life sustaining community by registering to be an organ, eye, and tissue donor? Will you make the commitment to become more educated about living donation and championing the donation cause? Shelly is associated with the Cincinnati, Ohito chapter of The Links, Incorporated and she served as the Health and Human Services Facet Committee chair. The Ohio central chapter was granted an award by Baxter International for increasing the awareness of kidney health in the communities in which Shelly lives and primarily in the African American community. What is GFR? Shelly has been working hard in the community to make sure people know where they are regarding their GFR, which lets them know how well their kidneys are functioning and what they can do to maintain kidney health. The Links organization was founded in 1946 on the premise of friendship, and Shelly wants to uplift and elevate people by providing health information. Stephanie and Shelly first met through collaboration with The Center For Closing the Health Gap. Shelly had goals in mind based on the grant they received regarding the number of people that they needed to touch and the number of community partnerships that they needed to do. Shelly and Stephaine share the experiences they have had with training sessions and connecting in the community. They hope people will continue to listen to the podcast and continue doing some things and spreading the word in their communities. When people are ill, you can see it on their skin and eyes. You can notice the effects of kidney and liver illness on the skin and other body systems. Garlic is great for decreasing inflammation; It has Vitamin C, Vitamin B6, and Manganese, a great alternative for your seasoning. If you want to decrease your psyllium, you can add more garlic, which is great for your heart and your kidney. The one thing is to avoid canned and packaged chicken breast because those can contain sodium and other preservatives. Raising awareness and making small changes goes such a long way in promoting healthier lifestyles. There is a great ripple effect too when you share information like this with those in your family and circles. 3 Key Points: Blueberries are an important food for kidney patients. They serve as antioxidants and are very good for healing. In addition, they help your body to increase urination. People talk about dialysis and transplant, and these are things that you want to avoid. By opting for a healthier lifestyle and changes in the food you eat, you can do that. There are so many ways you can just move your body, and Stephanie always tells people 15 to 20 minutes is sufficient. Make sure that your body is doing something that it doesn't do every day. Resources Mentioned: LifeCenter | Website | Facebook | Instagram | YouTube| Twitter Andi Johnson website |LinkedIn Organ Donation Website https://www.cincinnatilinks.org/black-kare-initiative https://www.facebook.com/CincinnatiLinks https://www.instagram.com/cincinnatilinks/ https://www.yoursweetestlife.com/ https://www.facebook.com/yoursweetestlifewithstephaniej https://www.instagram.com/yoursweetestlifewithstephaniej/
We learn what kind of research went into developing and articulating an EVP for a 90-year-old global brand, and what metrics they look at to see how it's working. Allison Kruse is the Head of Global Employer Brand at Baxter International. Allison Kruse on LinkedIn: https://www.linkedin.com/in/shana-andrews/ Careers at Baxter: https://jobs.baxter.com/ Subscribe to this podcast: https://employerbrandingpodcast.com Measure your employer brand: https://employerbrandindex.co Thanks for tuning in!
In Season 2, Ep 2 of the Best Boss Ever podcast, Christine interviews Laura Todd, Sr. Manager, Logistics & Customer Operations at Baxter International. Her best boss story begins when and after Fiona interviewed her. Laura was offered the job within three to four hours, which created a terrific first impression of confidence and decisiveness. Laura went on to really appreciate and value the diversity of talent of Fiona's team. The Best Bosses Ever possess many of these and other skills. Also, Laura shares the ONE tip Fiona excels at to attract and retain excellent, interworking talent at Baxter.
Christian Perez-Font has one of the most unique law practices I've come across. We spoke at a conference around three years ago, and we've kept in touch since then. I've had him come on several podcasts to talk about his analytical and data-driven approach to legal issues in the world of ESG. Watch ▶️ ESG Through a Legal Lens with Christian Perez-Font Key points discussed in the episode: ✔️ Christian Perez-Font gives us a background on his professional experience - a lawyer by trade who sees compliance as business support. He also defines the mantra of his company, Thinkeen Legal. ✔️ The right perspective going into data tracking and analyzing - seeing data as fuel for your business and a measure of progress. ✔️ The intersection of ESG and compliance in social responsibility and governance. ✔️ Manufacturing companies are cognizant of the environmental aspect of ESG. However, “E” goes beyond companies with plants subjected to carbon footprint regulation. ✔️ Data analytics is all about utilizing and presenting relevant data. Don't be the Instagram of corporations. You don't have to publish every number for investors to avoid the threat of transparency. ✔️ Track political contributions. Talk about diversity. ✔️ There are no a-ha moments in data tracking. Don't wait for the trends to pass. Start now, then it'll be easier to spot any spikes or changes so you can quickly make adjustments to your ESG program. ✔️ Data shouldn't be used to prove how good a company is. It should be to learn and know if you're on the right track. ✔️ The role of the auditor in data tracking. ✔️Data analytics and tracking play a major role in business acquisitions. Know as much as you can about the other. Understand the company's ESG program and have a clear grasp of its social responsibility and environmental footprint. ✔️ Trade sanctions and trade compliance have become a huge part of data analysis in ESG. ✔️Using data visualization to convince your board that the ability to present information is a valuable asset. ✔️Changing policies isn't a sign of weakness but of progress. Christian Perez-Font is the managing partner of Thinkeen Legal, a law firm that specializes in corporate and commercial law, domestic and cross-border transactions, and compliance with a focus on startups, small and mid-sized companies. His company has experience in many industries but we are particularly strong in healthcare. They also offer outside general counsel services to clients who are not yet ready to hire an in-house counsel or those in need of a secondment while they fill a position. They have significant external and in-house legal experience having worked for premier firms and multinational companies such as Arnold & Porter, Baker & McKenzie, Baxter International, Olympus Corporation, and OPKO Health, Inc. They have been clients so they understand that Legal is a business support function. His aim is to add value by delivering simple and pragmatic business advice with a legal content. Connect: https://www.linkedin.com/in/christianperezfont/ ---------------------------------------------------------------------------- Do you have a podcast (or do you want to)? Join the only network dedicated to compliance, risk management, and business ethics, the Compliance Podcast Network. For more information, contact Tom Fox at tfox@tfoxlaw.com.
In this episode I speak with Harry Kraemer Jr, former CEO at Baxter International and now professor of management and strategy at Northwestern's Kellogg School of Management whose wake up call was being told by his childhood Catholic priest to not become a priest and instead to go out and influence the world who need it most and don't worship a religion. https://harrykraemer.org/
Leaders Of Transformation | Leadership Development | Conscious Business | Global Transformation
Deborah Westphal has guided our era's top minds and leaders to challenge biases, ignite ideas, and build connections and resilience for a secure and sound future. Her career spans more than 30 years, government agencies and Fortune 100 companies, and virtually every continent. In 1999, Alvin Toffler tapped her as one of the founding members of his eponymous consulting firm, Toffler Associates. From 2007 through 2018, she served as the firm's CEO. Through her work, she has guided notable organizations including Lockheed Martin, Northrop Grumman, Marriott, U.S. Air Force, Baxter International, Bayer, Heinz, Microsoft, Koppers, PPG, DARPA, National Security Agency, Loral Space Systems, NASA, Qwest, Verizon, and Westinghouse. Deborah's empathetic and thought-provoking style helps leaders spot patterns that signify future risks and opportunities. She's a sought-after speaker and writer who provided the Foreword to After Shock. Deborah is a world traveler who enjoys time with her son and running in the mountains. What We Discuss with Deborah Westphal in this Episode The curiosity of a futurist The work of Alvin Toffler Advancing technology and humanity The power of “What if” questions Convergence and the forces converging right now Questioning the assumptions you have Business trends and how to prepare for the future Honeywell and making plastics recyclable From shareholders to stakeholders Are electric cars really clean? The impact of the internet on the environment Practical solutions for leaders How travel shapes our perception and understanding The importance of Antarctica to humanity How the environment impacts your critical supply chain Episode Show Notes: https://tinyurl.com/2c285jfx
Being a leader and teaching leadership are two very different things. Harry Kraemer found this out when he jumped S-curves later in life. Harry is the former chairman and CEO of Baxter International, a $12 billion global healthcare company. But more importantly for this conversation, he now teaches leadership at Northwestern University. Harry explains the importance of self-reflection and genuine humility, and identifies the nature of "true self-confidence." It's not about taking risks or getting up in front of people. By contrast, true confidence is a leader's ability to say "I don't know." Harry and Whitney discuss the qualities that make leaders both effective and relatable, and why it's never OK to say, "I don't know where you're coming from." Harry's most recent bestselling book is titled: Your 168: Finding Purpose and Satisfaction in a Values-Based Life.
David Faber, Leslie Picker and Mike Santoli explored the road ahead for stocks as the S&P 500 hits a fresh record high. A Wall Street analyst joined them to discuss Apple and Alphabet hitting all-time highs and how you should put your money to work in big tech. The anchors also discussed the remnants of Hurricane Ida, which battered the Northeast U.S. and resulted in massive flooding, record rainfall, tornados and deaths. Leslie showed video and a photo of her morning commute, which highlighted flooding and damage. Autos in the spotlight: Ford vehicle sales tumbled more than 33-percent in August. The anchors and Phil LeBeau discussed everything from Ford cutting back F-150 production in wake of the chip shortage -- to tech investor Cathie Wood tweeting that "Auto buyers are abandoning gas powered vehicles in favor of electric." Also in focus: Shares of Chewy fell sharply after the pet products retailer posted a quarterly miss, Didi and the China crackdown on tech - Beijing ordering eleven ride-hailing platforms to stop "unfair competition tactics", Baxter International confirming it is acquiring medical technology rival Hill-Rom in an all-cash deal valued at $10.5-billion, Hormel falls after downgrading its outlook, Why food company valuations are compressed, and the bankruptcy plan for OxyContin maker Purdue Pharma was approved by a federal judge.
US stocks rose Monday. Plus, Baxter International nears a $10 billion deal for Hill-Rom Holdings, Catalent buys Bettera for $1 billion, and Astra's rocket-launch test fails.
US stocks rose Monday. Plus, Baxter International nears a $10 billion deal for Hill-Rom Holdings, Catalent buys Bettera for $1 billion, and Astra's rocket-launch test fails.
David Faber, Morgan Brennan and Mike Santoli kicked off the show with the latest on the damage caused by Hurricane Ida, going to a live report from CNBC's Valerie Castro on the ground in New Orleans, which has been hit by a power outage -- more than one million people in Louisiana and Mississippi without power as a result of Ida, which was downgraded to tropical storm status. The anchors and a Wall Street analyst discussed Ida's impact on the energy sector, with regulators saying that 95-percent of oil production in the Gulf of Mexico due to the hurricane. David, Morgan and Mike also looked at the market week ahead with the S&P 500 hitting fresh record highs. Veteran strategist Ed Yardeni joined the program to discuss what he calls an "earnings-led melt-up" in the S&P 500. Space-related stocks among the big movers: Satellite services provider Globalstar soared more than 60-percent following a report in AppleInsider that the iPhone 13 will have the ability to utilize satellite communications, while Astra Space shares plummeted after its rocket once again failed to reach orbit. Also in focus: Shares of digital payments specialist Affirm Holdings soar more than 40-percent on news of the company's partnership with Amazon, China to limit videogames for young people, how insurance stocks are moving in reaction to Hurricane Ida, the EU suspends non-essential travel from the U.S. due to the Delta variant outbreak, plus medical technology M&A: David Faber reporting that Baxter International is near a deal to buy Hill-Rom for $156 per share.
Dow loses ground, while S&P 500 and Nasdaq set records again. Baxter International, Hill-Rom shares jump on deal talks. Crude oil falls 1% after Hurricane Ida's landfall. J.R. Whalen reports. Learn more about your ad choices. Visit megaphone.fm/adchoices
Gordon is a former corporate warrior who successfully delivered complex $100m projects, ran $300m departments, and led global teams of 1000 staff. He has helped clients reduce operational costs by $350m, increase performance by 50%-500%, and helped entrepreneurs triple their revenue in just 12 months. Now Gordon helps to develop good managers into great leaders and also helps those looking to take their first steps on the leadership ladder. He's also a highly sought-after keynote speaker on Leadership, Employee Engagement, and Operational Excellence. He's been recognized by Global Gurus as a ‘Top 10 Leadership Expert and Speaker. Gordon's work has been featured in Forbes, Business Insider, Inc., Entrepreneur, Fortune, and Addicted 2Success. He's written 4 books and his last book FAST was a finalist in the Chartered Management Institute Management Book of the Year. Clients include Accenture, GE Aviation, Allianz, Baxter International, Arizona Dept of Child Safety, American Airlines, and many others.z Find out more about Gordon and what he does at GordonTredgold.com. --- Send in a voice message: https://anchor.fm/tboc/message Support this podcast: https://anchor.fm/tboc/support
Baxter International is a global provider in healthcare solutions. They are at the critical intersection of saving and sustaining lives thanks to their products and therapies. In this episode, Joe Almeida, CEO of Baxter International, gives a behind the scenes look at the changes taking place to foster supply chain resilience as a result of Covid; as well as the innovative initiatives to help provide accessible healthcare to every American.
Our guest is Wayne Davis, ex-SVP of HR at Comcast and an HR Consultant. A Human Resources veteran with more than 25 years of experience, Wayne has developed and led human resources teams for several fortune 500 companies including Comcast NBCU, YRC Worldwide, American Greetings, Northrup Grumman, Baxter International, and Frito-Lay. In many of his roles, he has overseen the delivery of a comprehensive suite of HR solutions which include talent acquisition, organizational design, employee engagement, total rewards, succession planning, employee development, and workforce analytics. In this episode of Scaling Culture, Ron and Wayne discuss: Wayne's AHA moment and a shift from traditional HR to People & Culture mindset The Comcast Culture Transformation, “Flame Process” and the outcome of working together to win together Org design for the new path forward, before/after changes, challenges and impacts For more information about Wayne, please connect with him on LinkedIn For more information about the Scaling Culture Podcast or our upcoming book and Masterclass “Scaling Culture”, go to connollyowens.com
It’s been a year since we last spoke with our vaccine expert, Dr. Peter Khoury. We discuss the different types of vaccines available, if there is a best one to take, if there are side effects or dangers to be worried about, and whether or not Covid 19 will be here for the long run. Dr. Peter Khoury, is the President and CEO of Ology Bioservices Inc. He is an expert on vaccines and biologics and during his 30-year career, he has worked for the Bill & Melinda Gates Foundation, Merck, and Baxter International. Dr. Khoury has involved in international forums on vaccines, pandemic planning, and biodefense preparation, including working with the Olympic Committee. TRANSCRIPT: Intro: 0:01 Inventors and their inventions. Welcome to Radio Cade and podcast from the Cade Museum for Creativity and Invention in Gainesville, Florida, the museum is named after James Robert Cade, who invented Gatorade in 1965. My name is Richard Miles. We’ll introduce you to inventors and the things that motivate them, we’ll learn about their personal stories, how their inventions work and how their ideas get from the laboratory to the marketplace. James Di Virgilio: 0:39 Welcome to Radio Cade . I’m your host, James Di Virgilio. And today we are bringing you a special episode. It is part two of the, everything you need to know about vaccinations and COVID-19, it’s been almost a year since I last spoke with Dr. Peter Khoury, you can catch that episode anywhere you listen to this podcast. Dr. Peter Khoury is the president and CEO of Ology, Bioservices, he’s an expert on vaccines and biologics. And during his 30 year career, he’s worked for the Bill and Melinda Gates foundation, Merck and Baxter International. Dr. Khoury has been involved in international forums on vaccines, pandemic planning, biodefense prep, including working with the Olympic Committee. Dr. Khoury, welcome back to the show. Dr. Peter Khoury: 1:20 Thank you, James. And it’s unfortunate. We can’t do it in person. Certainly. I’m sure you, myself and others are so used to doing teleconferences and Zoom calls. So we’ll see how this goes. And hopefully you can hear me well. James Di Virgilio: 1:35 Yes, we can. We’ll make this work last time. In our first episode, of course we were together. We were in a large room sitting far apart, but it is always great to have, of course, the person you’re talking with in front of you, like all of the listeners know and understand as well. So since the last time we spoke, a lot of things have changed, but really a lot of things that you had talked about on the first episode have essentially come to pass. You mentioned there’d be a potential small wave of infections followed later on by a much larger wave of illness that certainly happened. And then we got into the discussion, which is really going to be the crux of our discussion today of essentially game theory and viruses, which again, viruses are smart. They react, they change, they have different strands. I think a lot of the public across the world has learned about these things. And how do you deal with them? How do you stay one step ahead. So let’s open up now with that in the background and ask you sort of this big question, looking back now, what happened that maybe you didn’t foresee the first time we spoke? Dr. Peter Khoury: 2:29 There’s a couple of things and they, I guess aren’t really biology related, but they really did make an impression on me and were something I did not foresee. The first really was the amount of compassion and caring that people show when they’re in uncertain circumstances. It did once again, show me that compassion is an inherent trait and caring helps ease the burden. A pandemic can cause think about the long hours and risks that healthcare workers put themselves in, especially at the beginning of COVID-19. And there was so much unknown in so many people being infected and to be an emergency room nurse or physician at that time, and having to put in those long hours and put yourself at risk and your family at risk and not really sure if one mask or two mask or a shield or what exactly was going to really protect you, but they came in for work day after day, policemen, firemen, emergency workers, all of them. It’s amazing for them to really take care of those who had severe cases of COVID-19. So I think that’s the first thing that I didn’t really foresee that there would be that kind of positive response. And so many people that really took up caring for others. The other thing that I didn’t foresee was the ability of people who may otherwise be intelligent to actively ignore the science and the data. And instead believe what I thought were ridiculous, conspiracy theories and false information generated by self-proclaimed experts whose credentials are measured by the number of people who follow them on social media. So I was surprised by that, that otherwise people that I thought were pretty intelligent would trust that for their information instead of the experts in the field. Actually, there is another thing, a third thing that I didn’t really foresee a year ago, and that’s really how different people’s tolerance for being inconvenienced and then their mental calculation of the risk and reward removing something that is inconvenient. So simply stated their reasoning for justifying doing something that increases their risk . I happen to live out towards one of the most populated Springs in the area. And it was amazing during the weekends of this past summer, the hundreds, if not thousands of people that would go to these Springs and no mask, no nothing, whole family. And they would put themselves at risk. And it’s hard for me because I wouldn’t do that to actually see that. And now here we have, I think at least two States, Texas, and Mississippi that are basically taking down everything, no mask, full restaurants, everything back to normal, and I’m afraid. We’re just going to see another huge wave from this. So people need to understand, yes, you’re going to be in convenience for awhile , but that’s the only way to stop spreading a virus like this. Or of course, get everyone vaccinated and protected at least to a number where you get protection of the movement of the virus amongst a population. James Di Virgilio: 6:05 Yeah you mentioned an interesting narrative there with listening to experts and in my own field of investing, I like to tell people all the time, if you ask me questions about investing, I can speak as an expert in the past. This is why this strategy worked here are the data sizes and samples. Here’s the research done here. So we know it’s worked in the past. Here’s, what’s likely to work in the future, but if someone asked me six months from now, what exactly is going to happen in this market or this investment? The only right answer is, I don’t know, and neither does anyone else. And there seems to be some confusion between experts that know how to speak on things that have occurred, that they’ve witnessed and people making prognostications, using whatever kind of modeling, either simple, or as you mentioned, an opinion that comes from your mind and gets put onto social media, prognostications are difficult, but the hard data, the data we’ve observed, the data we know to be true of course tells a different story. And that I think is what you’re looking for. Obviously in a free society for people to begin to clean to what is the truth are things that we’ve observed before. So let’s set the stage for vaccinations. In general, last time you had mentioned, there’s essentially five main ways that you can create a vaccine to overly simplify and with Corona virus with COVID, we have essentially not used all five of them. If you could kind of walk through the landscape right now for the vaccines, we have the ones that may be worked on, and then we’re going to walk through them because I know that’s a huge question area for most people. Should I get an mRNA vaccine? Should I wait? What’s the difference? Is it risky? So if you could set that landscape again, what these vaccines are, and then we’ll dive into each one and give everyone out there a good chance to grasp what the differences are. Dr. Peter Khoury: 7:41 Sure. And I have to admit, I didn’t listen before this, to what I had said a year ago, but there are tried and true methods for making a vaccine, whether it’s a live attenuated vaccine, where they take either a virus or bacteria and they make it. So you have, what’s called a subclinical infection where you don’t really get sick from it, but your body responds as if you did. So you produce antibodies and an immune response to this modified bacteria or virus that’s been attenuated, or sometimes you just kill it and put it in hall in the person. An example is at the early days of vaccines, the very first one was a smallpox vaccine made with Cowpox. And they realize that milkmaids were not getting serious cases of smallpox it’s because they were infected with cowpox, which was a milder version. And that’s sort of like an attenuation in a sense. And so then they were able to take that and literally just bake it or whatever you want to do to kill the bacteria and use that. Then as a virus itself, you can also put it in a mixer and slice it up and you have a bunch of small pieces of a virus or a bacteria. And I say a mixer. It’s nothing like that, but you get the idea of slicing it up and in your body sees that as foreign. And it can develop an immune response to that. But the vaccines that are now on the market actually use newer technology, which really is ingenious. And unfortunately people fear mRNA’s or DNA and they think, Oh, this is genetic engineering. And they’re putting something into me and it’s integrating into my chromosomes. And I don’t know, the government can track me because of that. And it’s nothing like that. Really. If you look at it in the science behind cell biology is just amazing what each of your cells can actually do. And it’s really using that mechanism as a small factory in itself. So I think most people realize there’s a third vaccine that was just approved by the FDA, by a company. You know, them as Johnson and Johnson, they have a subsidiary called the Anson, which is out of the Netherlands, their vaccine portion of the company. And so this new vaccine just came on the market. It’s given us a single dose and the other two, which had been around now for a few months, the Pfizer in Moderna vaccines, those are really two dose vaccines. And so the Pfizer Moderna vaccine utilizes this manufacturing platform that you mentioned, which is mRNA or messenger RNA. What they do is they have this piece of genetic material that in a sense codes, it’s the recipe, for what’s called the spike protein or part of the spike protein, which is part of the Corona virus. And they encapsulate it in like this fatty particle. So it’s called a VLP. And so inside this, let’s say glob of fat, little glob of fat is this little piece of genetic code. Well you’re cells need energy. And so when they see that they use that for energy, this gets injected in your arm and your cells in your arm , see that those fatty particles and they start sort of sucking them in for energy use. And as they suck them in. And the middle is this little piece of genetic material, which is the messenger RNA once inside the cell . Well , your body has all the mechanisms to take that recipe, which is in a sense listed on this piece of messenger RNA and start producing the protein it’s encoded in it, which is that spike protein. So that spike protein is then released from yourselves and other cells. See, it may say, Hmm , that’s not part of our body that’s foreign to us. And so it generates immune response by your other cells, by your immune cells. In those remember seeing that particle after it eats it up or whatever. So it sees this spike, protein decides it’s foreign to your body. The immune cell then ingests that, but it remembers seeing it. So if you’re ever infected with a virus, your body immediately elicits an immune response. You don’t even know you were infected because antibodies instantly take up the Corona virus that you’ve been infected with. And that’s how you’re protected by that type of vaccine. Johnson and Johnson vaccine actually uses a different type of technology. They use what’s called a viral vector in what that is. It’s a virus, the one they use is called adenovirus, 26. It’s basically a virus that’s similar to what the common cold viruses is. They genetically engineer that. So it can infect cells, but it won’t replicate inside the cells. So it can’t spread throughout your body and give you any kind of infection or whatever, but it does have inside of it , the genetic instructions like that recipe again, to make that spike protein that is used to elicit an immune response. So instead of being carried in these little fat or lipid balls, the genetic instructions are injected by that weakened virus into the arm cells. And then they make that particle, which is the spike protein of the Corona virus. And that again is identified by your other cells as being foreign in your body. And it elicits the immune response. So that’s sort of the mechanisms for the three different viruses. Again, hearing that people consider that genetic engineering, you know , I just want to set the record straight. There is no modification of your genetics or of the virus genetics. So what is happening is, as I said, it’s truly amazing. If you think about that, the cells in your body, which have all the machinery to make any kind of protein, it has the recipe for that’s what’s included on your chromosomes are all these recipes for proteins that make your eyes a certain color and your hair, a certain color, et cetera, all it’s doing is simply introducing a new recipe, which either is delivered by a harmless virus that won’t replicate or that’s provided in like this little energy bar, these little lipid fat balls, and that recipe delivered uses the cell machinery to make the part of the spike protein that causes the immune response. Sorry, that’s a long-winded answer, James. James Di Virgilio: 14:41 No, it’s a good start. So mRNA founded in 1990 or so essentially by a Hungarian scientist, she had this novel idea and then all the way up until COVID-19 was never used or approved. Should there be concern that it now for the first time is being used in a vaccination that is going to be used worldwide. If it’s never been used in the real world before. Dr. Peter Khoury: 15:04 Now, it really should not be in the reason as is it does not modify your genetics at all. It literally is just, as I said, use the mechanism of your cell to produce a protein. I’m trying to think if there’s any other comparable in either veterinary medicine and nothing’s coming right to mind. But as I said, it’s not genetic engineering by any means. It’s literally putting a small piece of messenger RNA, which is normally in your body. So your chromosomes, which are DNA are transcribed into messenger RNA, which is read to make the proteins, this just skips the DNA part and goes right to the messenger RNA. James Di Virgilio: 15:47 So we don’t have to worry as the public, as far as we can tell scientifically that this is going to turn into something that’s going to alter body chemistry cause sickness down the road have any longterm effects. As far as anyone can tell. There’s nothing about these MRNs current vaccines that we should be afraid of. Dr. Peter Khoury: 16:03 Right. And it’s new technology. You really can’t tell the future. All indications are that it’s very safe in very efficacious. The amount of clinical studies that go behind products like this before they’re released is truly tremendous. I think that there would have been clear indications as they were either studying this technology early on or as it gets further on and goes through the phase one phase two and finally phase three clinical studies that there would have been warning signs that there were problems, but certainly none have arisen yet with this technology. And if you think about it, theoretically, there really is very little, if anything that could rise from having this done, but you never know until time’s passed. James Di Virgilio: 16:55 Right? The famous French economist in the 1840s, Frederick [inaudible] would talk a lot about unintended consequences of whatever you put in place in society. There are always unintended consequences that you cannot foresee, but scientifically it is good to note like you’re mentioning as far as anyone can tell scientifically this is not injecting a large risk into your own body. It is not altering genetic code, as you mentioned. Um , and that that’s , that’s something to hang on. So now let’s talk about something more nuanced. So we have two mRNA vaccinations that are available. Obviously big advantages are it’s much faster to bring them to market logistically before we get into the other ones. Are there any hurdles with an mRNA vaccination logistically with regards to freezing or refrigeration or transport that maybe would give a more traditional vaccination at advantage and delivery and rollout ? Dr. Peter Khoury: 17:41 Yeah, actually there is. I know with the mRNA vaccines, as far as the fats surrounding it, the VLP structured itself needs to be kept at low temperatures. So would that Moderna and Pfizer vaccines, the storage in shipping was between minus 80 centigrade minus 60 centigrade. So that’s minus 112 degrees Fahrenheit to minus one 76 Fahrenheit. So that caused a lot of trouble at first for States or for injections sites and clinics because they didn’t have those special freezers. We have them because of the work we do here, but they’re just not readily available. People don’t keep these in physician offices , et cetera. But what they did do is immediately started looking at temperature changes and how long the vaccine in a sense could survive at regular refrigeration temperature or in a freezer, regular freezer. So the FDA did ease up on those requirements, but even now that vaccine still only can be held in a refrigerator for five days and then must be used within six hours of being thawed and diluted. So there is a small window, and it’s because of those VLP that ball of fatty acid , that carries, that, that makes it. So you have to have careful handling per both the Johnson and Johnson vaccine, which uses the adenovirus actually can be kept at refrigerator temperatures for up to three months. So it’s far easier to store and ship because of that. Another difference between these one, as I mentioned is a one dose vaccine and that’s the Johnson and Johnson vaccine in the Pfizer and Moderna, the vaccines are both given as a two dose series. Obviously giving one dose is much easier since there’s no follow-up visits, which involves making sure the person in the vaccine are there at the right time for dose number two. So coordinating all of that goes away, where if you do have to come back for a second dose with the Pfizer/Moderna vaccine, you obviously have to coordinate it. So the person and the doses they’re at the appropriate time to administer at , but there are clinical studies were done a little differently. So when you look at the efficacy of Pfizer and Moderna, those vaccines had a rate of effectiveness during the clinical trials of 94 to 95%. So that means that they vaccinated people and they looked for antibodies production. In those people. It makes sense . Every hundred people that we vaccinated basically 95% over, I think it was four weeks had developed immunity by , in contrast with the Johnson and Johnson or the Yansen vaccine, they said it was 85% effective against severe disease and a 100% effective at preventing death. So during their clinical trials, not one person who got the vaccine. And I think there were 44,000 died from COVID-19. And I think 100% didn’t even go to a hospital. There were some people that did have severe disease about 15%, and there were people that had what they call moderate to severe illness. So that would be in a sense they were home, not feeling well, et cetera. So it’s hard to compare apples to oranges. In this case, since one was a two dose vaccine looking purely at efficacy and production of antibodies in the other was a one dose looking at severity of illness. So getting either vaccine is a great thing to do. If you get the one dose vaccine, you don’t have to go back for a second dose, but there is some chance that if you’re exposed to COVID, you may get a mild illness from COVID. And in fact, there’s a lower chance of only 15% that you could have a severe illness from that. We don’t know if you’ll die from it, but for the 44,000 people they had in their clinical studies, I think it was 44,000. None of them died from illness. So I think those really are the main differences. There’s a little difference as far as how quickly you’re protected that Johnson and Johnson vaccine works about two weeks after people get vaccinated with Madonna and Pfizer people don’t get full protection until about two weeks after the second dose. And the second dose is usually three to four weeks after the first dose. So from the very first dose, you’re talking five to six weeks after the first dose and you’re fully protected. James Di Virgilio: 22:53 Let’s bring this down to the granular level now and get to a decision point. So let’s assume, and I’m going to throw a fourth one in here with Novavax, which may or may not come through, but it’s another different type vaccine just to give us the thought experiment of being, let’s say late August, you haven’t had a vaccination yet. And you have this choice in front of you. You essentially have the mRNA, which you’ve mentioned is Moderna and Pfizer. You have Johnson and Johnson, and then you have Novavax, which is going to be one of the most traditional and time-tested vaccinations. If it makes it again, we’re speculating here, just to give an idea of what this may look like, and you have a choice. Does it matter Dr. Khoury, which one you choose? Is it simply saying, you know, it doesn’t really matter. Take either one of these for convenience or one you can follow through on, or is there a more educated decision that needs to be made if you’re facing a choice between these let’s call them three different vaccine deployments, Dr. Peter Khoury: 23:44 Right? Of course, a choice like that is personal on whether people want it to be vaccinated or not. I would say that the first hurdle is get vaccinated. There is no doubt that vaccination protects you when it comes to the choice. And there are so many people in videos, out of people, literally on their death bed, dying of COVID by themselves, in a hospital saying, I wish I had not gone to that party. I wish I had done this or that. You may think you’re otherwise healthy, but you’re playing Russian roulette with something that impacts people in very different ways. Even though they think that I’ve never been sick in my life, this couldn’t impact me. You would be surprised at the number of younger people and other people that get this disease and either suffer long-term consequences from that, or truly die within a few weeks of contracting the virus. The question is if you had the choice of vaccines, which one based on the technology used would be better. I always tell everyone if it’s been reviewed by the FDA in the United States or the other one is the Korean FDA. Korea has an incredibly competent FDA based really off the US FDA and both are very, very good at looking at the risk and rewards of every vaccine, European union, also very particular and conscientious about looking at the impact of vaccines. So I would say that if it’s been approved by the FDA in the United States, it’s a safe and effective product . So if Novavax does get approval, I would not hold back at all on getting that vaccine versus either Moderna Pfizer or the J&J products. All of them are winners. If you get at , if you’re needle shy, obviously you may want the one dose versus the two dose. So there may be some advantages mentally for you there. If you want to make sure the odds of being protected the best look at efficacy after two doses, it’s much higher than it would be after one dose. But again, all of them are safe, effective vaccines, and the technology makes very little difference in this case. James Di Virgilio: 26:12 So the take home there is assuming that they all have FDA approval and you have that choice. The reality is you don’t need to spend a ton of time researching which one to get, because the odds are, all of them, of course are going to work for you. And there’s just different sort of personal mechanisms. Like you mentioned one dose or two things like that. But right now there’s not a significant difference that should have you necessarily favoring one over the other. If you’re looking to get a vaccine. Dr. Peter Khoury: 26:37 Right. Just based on the last sentence you mentioned, I’m not sure what the composition is of the vaccine that may come out later on this year, but I know the Moderna, the Pfizer, the J&J vaccines do not have adjutants in them. So in they’re not produced like an egg. So if you have an allergy to eggs or egg protein, it’s no issue with these vaccines. If you have been issue , there’s what are called adjuvants, they help boost the immune system with certain vaccines. None of these have this. So they’re pretty pure vaccines. Some of the older technology you’ve had to use either a chicken, eggs, or hens eggs to produce the product. I think the one you had mentioned is a Viro cell product . So it is not produced in, in hens eggs, but some of that older technology does use adjutants and other things, which is that chemical treatment. So some people have had reactions to that in the past. James Di Virgilio: 27:39 To look for individual things that maybe you yourself have an allergy to, or , or some reaction to, but all in all, if it gets FDA approval at this stage, it’s gone through the rigors. And if you want to get a vaccination again, no need to sparse out exactly which one to get. The differences are not going to be, as you mentioned significant, despite the fact that they are in fact different delivery mechanisms. Now let’s talk about different variants. This has obviously gotten a lot of news play here. When we first talked, we talked about how stable COVID-19 was. Uh , we also talked about, of course, the fact that virus has changed and that we could expect COVID-19 to change. We just didn’t know how yet, given what you’ve seen with the variants . And we know we’ve seen numbers, Johnson and Johnson is almost 70% effective against variants. Each one of these is a different number. What is this variant landscape look like to you? And I know you don’t see the future, but as of right now, if I get a vaccine tomorrow, do I have decent protection against the variants we’re aware of right now? Dr. Peter Khoury: 28:32 Yeah . It’s important that people get vaccinated as quickly as possible because the quicker we can shut down the circulation of this, the chances of it mutating in doing what I had talked about is drifting and shifting gets eliminated. So through replication, that genetics change is virus adapt to their surroundings, just like humans do. If you look back at Neanderthals and us you realize that certain people are born with traits that allow them to survive better. In certain circumstances, that’s true with virus and bacteria. It just happens thousands and thousands of times faster than we replicate. So literally in 24 hours, virus have gone through 10,000 fold replications where humans takes nine months to birth out a baby. And it literally happens so fast that these genetic changes in that adaptation to your surrounding can happen very quickly. And as long as those changes have little impact on the spike protein, that’s a protein has been utilized by all manufacturers that I can think of as the target for the immune response, then really vaccinating now should protect you against most of the variants. The variants, it wouldn’t protect against would be ones that have totally shifted away from that current spike protein configuration. So if there’s a little drifting away that protection will go down a little bit. Some people won’t be protected as well, but if there’s a major shift, it doesn’t provide any protection. Now you don’t know if that’s going to happen. I talked to other people that are experts in the field, and some believe what’ll happen is this’ll become like the yearly flu vaccine that will be able to see the shifting happening in other parts of the world. And people will just change the messenger RNA or whatever it is that’s coding for the latest variant that’s circulating around the world. And then a few years later, if it changes again, you need to get another dose of vaccine against that. I’m hoping we don’t have to do that. I’m hoping that we’re able to shut this down as quickly as possible and make it just a one-time pandemic event and basically eliminate it from the world soon. James Di Virgilio: 31:03 And that’s a great point. And that’s something again, that wisdom would say, no one knows the answer to that question, but certainly we hope that COVID is not here to stay like influenza or influenza has some mutation strains that become very famous, like the Hong Kong flu in the sixties, for example, right. That’s influenza just a different strand. It’s still here today. Obviously it’s just not that significant bumps. So that’s a , we’re all hoping for, as you mentioned, and of course, like you said, one of the best ways to make sure that happens is if everyone does get vaccinated faster than you’re going to give this virus less of a chance to make these game theory changes, to look at what humans are doing and respond and say, okay, well, I’ll do this to try to keep myself alive. Essentially you’re reducing its options. And if you’re doing this options further enough, it may just totally be gone. Of course, that is over simplification . So here’s a question for you. What happened to the flu in this flu season? The CDC records indicate that the flu is essentially non-existent despite about a million tests. You’ve had very few positive results at all. Hospital admissions are down to levels, never seen before. What does influenza and COVID have to do with each other? What does this mean for the future? Any thoughts on that? Dr. Peter Khoury: 32:10 What we may be seeing is just impacted by the distance. People keep from each other and making sure they’re washing their hands, wearing masks, all of that impact flu also the transmission of flu. So I think flu is still here. There are cases, but people have become very conscientious about spreading viral diseases during this time. I think once the unmasking happens and people are back to what we consider a normal life, I think you’ll see dlu come back to the levels that it was before. James Di Virgilio: 32:50 Yeah. It’s an interesting thing to follow, obviously, because one of the major fears was, you know, what if you had COVID and influenza stacked on top of each other, and we don’t know yet how much these things co-mingle. Do you get one and not the other, can you get both in States like Florida, which had been largely open, you still have extremely low or non-existent really statistically influenza cases. There’s just a lot that we will unpack obviously in the future. All right . Let’s ask you this big question before we talk about what you were working on to close up today’s episode. So let’s put you in hindsight mode a year ago. If you knowing what you know now had the power to implement one change to impact the outcome of what we’ve gone through in the past year or so, what would that change have been? Dr. Peter Khoury: 33:30 Hmm , I think if truly there was a chance of getting all governments in the world together. I mean, that would potentially never happen. But I think in hindsight, if they were able to take a year and take a look at where we are now and the impact that it’s had on people’s lives. So the morbidity, the mortality, the impact on economics, all of that. And you could take all the decision-makers to this time and look back. I think all of them would agree that if we literally shut the world down for a week, made everyone stay home, put in very, very serious measures, whether it was a week or even two weeks that we could have stopped this right at the beginning, it literally wouldn’t have been able to become what it did. And if you look back at countries going to use Korea as an example where they did exactly that, or China or India, here’s a country with over a billion people and boy did an impact the number of cases they had much less than we have, but it’s an inconvenience obviously to do it. And if we had done something like that worldwide for a week or two, of course, people would have been inconvenience without knowing in the future of the impact or what that could prevent from happening. So looking back and having that hindsight now it’s nothing I could have done alone or whatever, but that would have been my advice to get as many people to stay home and watch Netflix or whatever you want to do for two weeks. Just get ready, implemented day that it starts in the day and the day it ends and enforce it . James Di Virgilio: 35:10 Yeah. It’s so interesting that the topic for a whole different podcast, like you mentioned, the hindsight hindsight analysis is always undefeated because you have information you don’t have. And as you mentioned, the question then becomes, how many days is it? How long is it? What if it doesn’t work the way we think it works? So then what happens is there’s a lot of decision points, but that’s why it’s a hindsight question is knowing what we now know that it did spread, it was highly contagious. It was going to go all over the world. Of course, as with any virus, if you can isolate you reduce the spread, right? It’s like playing tag as a kid. If you’re too fast and they can’t touch you and tag you, then you’re not going to be it. And so , uh , that’s an oversimplification, but that’s a good point about potentially the future. What do you do the next time this happens and what happens if it does fade away and its own. Okay. Will you said we lost 14 days, 14 days, certainly a lot better than a year. So lots of interesting thoughts there, let’s bring this right back down to what you and your company are working on. Tell us a little bit about an update. Last time we spoke, you are working on something COVID related. Tell us what’s going on with that. Dr. Peter Khoury: 36:07 Yeah, so we work with the US government on a couple projects, specifically with the department of defense to help protect military personnel and war fighters. And so we manufacture a vaccine for COVID-19 and we manufacture what are called monoclonal antibodies, which are also utilized to protect and treat, actually treat COVID infections. Both of these are in clinical studies. Currently we are expanding here in the Gainesville area. We’re in Alachua, we’re doubling our capacity . So the construction is underway for this. And I think it’s a great opportunity for this region because of University of Florida, some of the great research that goes on at that university in gene therapy and cell therapy, and in vaccines, it makes a lot of sense for us to make an investment, expand our workforce. So we’ve almost doubled our workforce. Since I last spoke to you, we’re over 300 employees during 2021, we expect to expand by over a hundred more employees. So there’s a lot happening here. All of that, very cutting edge science and all use to provide protection against infectious diseases. James Di Virgilio: 37:34 And let me bridge a gap here, because this could be maybe the best way to end this podcast. You obviously are an established expert in this field. You’re an expert on viruses on vaccinations, on deliveries. You’ve done it for your whole career. If you saw something that you thought was risky or reckless or not good for society or the population I’m imagining you would be standing on the rooftop, shouting this out, don’t take this vaccination, don’t do this. This is not safe. That would be correct. Dr. Peter Khoury: 38:01 It’s funny, James, because those that know me well, including our employees here, know that I speak the truth, I have great courage of conviction about what I say. My father was a United Methodist minister. My mom was a nurse that took care of some of the riskiest patients and both were just devoted people to what they did. And I think one of the most important things for any human being is their own dignity and not being able to stand up for what you think is right. And when you see something that, especially if you’re a professional and you know, information, not raising your hand saying that there’s an issue in something’s wrong is not good at all. So it’s not part of my being to ever cover anything up or whatever. And that’s a philosophy actually of our business here. I attend every one of our new employee orientations. And I tell them that everyone has the right to stop the process. If you see something being wrong done, or you’ve done something wrong immediately, we will stop. We’ll look at it, figure a fix and find a way of putting a parameter around it. So it never happens again. That’s all I care about. No one’s getting fired. You’re not going to be yelled at. We’re going to find a way. So it doesn’t happen again and fix what happened. That’s all there is to it. James Di Virgilio: 39:27 Yeah. That’s such a great commitment. And I think that perhaps is something that’s really gotten lost during this pandemic, is that not everyone is on two sides of offense fighting with each other and not every expert one way or the other is out there just trying to run a political agenda. It’s safe to say that many people are doing exactly what you said. Hey, if I think this science looks good or this looks good, I’m going to say this is safe. And if it’s not, I would say the opposite. And perhaps that bridge, as we mentioned, is something to move forward as a free society in the future. We’re looking for truth via evidence and data. And recognizing, as you mentioned, there’s a lot of people with that, very commitment. You’re simply trying to follow the evidence and say, Hey, look, I think this is what’s best for you and your family. You’re my neighbor. I love you. I care for you. And this is why I’m saying that. So a wonderful stuff as always, thank you for being with us. He is Dr. Peter Khoury, the president and CEO of Ology, Bioservices. You can find them on the web with a quick Google search. And of course, as we mentioned before, your illustrious bio, an expert on vaccines and biologics, and certainly one of our favorite guests here on the Radio Cade podcast. Thank you for spending a considerable amount of time with us today, Dr. Khoury. Dr. Peter Khoury: 40:29 Always my pleasure, James, thank you. James Di Virgilio: 40:31 And for Radio Cade I’m James Di Virgilio. Outro: 40:35 Radio Cade is produced by the Cade Museum for Creativity and Invention located in Gainesville FL. This podcast episodes host was James Di Virgilio and Ellie Thom coordinates, inventor interviews, podcasts are recorded at Heardwood Soundstage, and edited and mixed by Bob McPeak. The Radio Cade theme song was produced and performed by Tracy Collins and features violinists , Jacob Lawson.
It's been a year since we last spoke with our vaccine expert, Dr. Peter Khoury. We discuss the different types of vaccines available, if there is a best one to take, if there are side effects or dangers to be worried about, and whether or not Covid 19 will be here for the long run. Dr. Peter Khoury, is the President and CEO of Ology Bioservices Inc. He is an expert on vaccines and biologics and during his 30-year career, he has worked for the Bill & Melinda Gates Foundation, Merck, and Baxter International. Dr. Khoury has involved in international forums on vaccines, pandemic planning, and biodefense preparation, including working with the Olympic Committee.
Time is running out to register for the series' first offering, Challenges for Healthcare Leaders. On Feb. 23, Harry Kraemer, former CEO of Baxter International, will lead a live webinar and share how a values-based approach to leadership ultimately proves to be the most effective means to manage change in an evolving landscape. Learn more and register today.What did you think of the podcast? Contact AHIMA's Mike Bittner at michael.bittner@ahima.org.
In this HCI Podcast "Throwback Tuesday" episode, Dr. Westover talks with Lee Eisenstaedt about effective leadership characteristics, particularly the importance of self-awareness and humility (originally aired 5/20/2020). See the video here: https://youtu.be/9rOykZumTes. Lee Eisenstaedt (https://www.linkedin.com/in/leeeisens...) brings more than 35 years of diverse leadership, finance and operations experience to the clients of the Leading With Courage® Academy (https://www.lwcacademy.com/). The CFO of SC Johnson has described Lee as a well-rounded businessman because he's “…worked for more than two companies, in more than two functions, in more than two countries.” Lee focuses on helping individuals and teams, in employee- and family-owned organizations, realize peace of mind and confidence from being more effective leaders and managers. This is accomplished with the leadership workshops and assessments and a process for succession planning offered through the Leading with Courage®Academy which are based on his fourth book, Leading With Courage: The Nine Critical Behaviors of Effective Leaders and Managers (June 2019). Prior to founding Leading With Courage® Academy, Lee was a founding partner of L. Harris Partners, LLC, during which time he surveyed/interviewed several thousand clients of professional services firms. He has been a Chief Operating Officer of a Top 5 and a Top 50 CPA firm. Lee spent the majority of his career, 22 years, with the SC Johnson family of companies –including the consumer products company, the SC Johnson family office, and Johnson Outdoors, Inc. – in the U.S. and Western Europe, frequently as the“right hand” to the leader of the division, subsidiary or country to which he was assigned. During his two European assignments with SC Johnson, Lee lived and worked in Paris, France for five years and had responsibility for finance, accounting, logistics, IT and customer service in five countries within the European Union. Lee also spent six years with Baxter International, Inc. in various finance and accounting positions. Ranked in the Top 15 Personal Development and Self-Improvement Podcasts: https://blog.feedspot.com/personal_development_podcasts/ ; Ranked in the Top 30 Leadership Podcasts: https://blog.feedspot.com/leadership_podcasts/ ; Ranked in the Top 15 HR Podcasts: https://blog.feedspot.com/hr_podcasts/ ; Ranked in the Top 15 Talent Management Podcasts: https://blog.feedspot.com/talent_management_podcasts/ ; Ranked in the Top 10 Performance Management Podcasts: https://blog.feedspot.com/performance_management_podcasts/ ; Ranked in the Top 10 Workplace Podcasts: https://blog.feedspot.com/workplace_podcasts/
Harry Kraemer, Jr. from the Kellogg School of Management, and former Chairman and CEO of Baxter International, talks about faith, life balance, and the importance of self-reflection, from his book, "Your 168: Finding Purpose and Satisfaction in a Values-Based Life."
Harry Kraemer is the former chairman and chief executive officer of Baxter International, a multi-billion-dollar global healthcare company. He is a professor of management and strategy at Northwestern University’s Kellogg School of Management. He is also an executive partner with Madison Dearborn Partners, one of the largest private equity firms in the United States where he consults with portfolio CEOs. His third book is “Your 168: Finding Purpose and Satisfaction in a Values-based Life.”In this podcast Harry shared some war stories of tough decisions he had to make as a CEO. He shared his 40-year long practice of self-reflection and questions he asks himself every day. We also spoke about the importance of values in helping align stakeholders when tough decisions need to be made.
In this HCI Podcast episode, Dr. Westover talks with Lee Eisenstaedt about effective leadership characteristics, particularly the importance of self-awareness and humility. See webinar verion here: Lee Eisenstaedt (https://www.linkedin.com/in/leeeisens...) brings more than 35 years of diverse leadership, finance and operations experience to the clients of the Leading With Courage® Academy (https://www.lwcacademy.com/). The CFO of SC Johnson has described Lee as a well-rounded businessman because he's “…worked for more than two companies, in more than two functions, in more than two countries.” Lee focuses on helping individuals and teams, in employee- and family-owned organizations, realize peace of mind and confidence from being more effective leaders and managers. This is accomplished with the leadership workshops and assessments and a process for succession planning offered through the Leading with Courage®Academy which are based on his fourth book, Leading With Courage: The Nine Critical Behaviors of Effective Leaders and Managers (June 2019). Prior to founding Leading With Courage® Academy, Lee was a founding partner of L. Harris Partners, LLC, during which time he surveyed/interviewed several thousand clients of professional services firms. He has been a Chief Operating Officer of a Top 5 and a Top 50 CPA firm. Lee spent the majority of his career, 22 years, with the SC Johnson family of companies –including the consumer products company, the SC Johnson family office, and Johnson Outdoors, Inc. – in the U.S. and Western Europe, frequently as the“right hand” to the leader of the division, subsidiary or country to which he was assigned. During his two European assignments with SC Johnson, Lee lived and worked in Paris, France for five years and had responsibility for finance, accounting, logistics, IT and customer service in five countries within the European Union. Lee also spent six years with Baxter International, Inc. in various finance and accounting positions.
In this episode, we speak with Rich Boyer, MD, PhD who is a PGY-4 resident anesthesiologist at Massachusetts General Hospital in Boston. Rich has a unique background. He has a PhD in biomedical engineering, and an MD degree, both from Vanderbilt University. While matriculating at Vanderbilt, he worked with the institution to establish their pioneering MD/PhD Medical Scientist Training degree program. Rich has invaluable industry experience as well. He worked as an R&D engineer at Baxter International, and then served as co-founder of medical device startup Volumetrix, which was awarded NSF Phase I STTR & NIH Phase I/II SBIR grants for the development of wearable hemodynamic monitors. Anesthesiologists play a variety of critical roles in a hospital setting, in terms of providing anesthesia support for surgery, as well as critical care and pain management, giving them a broad perspective. He’s also a Research Fellow in their Cardiovascular Research Center. He and his fellow anesthesiologist residents have been doing their intense daily rotations in the ICU as the COVID19 pandemic spiked. Rich first conceived of the challenge while being quarantined after exposure to an infected patient. A strong team player, he wanted to contribute while in isolation. At first, he thought that he would design a ventilator using his biomedical engineering skills. This evolved into an open call to designers to design medically effective, affordable ventilators. He recruited his fellow residents to join the team, and they launched the CoVent 19 Challenge. They then assembled a core group of in-kind sponsors to provide a range of tools software, and resources to support the team’s efforts, including MCAD and requirements - driven design software, 3D printing, Biomedical Engineering consulting as well as a 24 hour Slack channel for real-time support from a broad range of medical and biomedical engineering experts. When not in ICU, he and his core team have been managing this global rapid ventilator design challenge, a strong indication of their selfless character. The team set up as a 501(c)(3) non - profit with the intention to share the designs openly in order to make them available wherever they are needed. Just 30 days from the launch of the Challenge, 213 teams submitted designs from 43 countries around the globe. On 5 May, 7 teams were chosen as finalists after an exhaustive review by a panel of world class experts. Teams range from faculty and alums at Stanford University and Smith College to a teacher and high school students at the Baxter Academy to a lone inventor in the UK, who recently won the Queen’s Prize for Innovation. Each one of the teams has a very compelling backstory and all have very inspiring motivations that compelled them to participate. The teams will now have about 3 weeks to create a working prototype, before a final winning design will be selected and move into production. They are being given a significant amount of on-going support to complete their designs and bring them to life. Disclosure: Co-host Mike Grandinetti is a member of the Board of Directors of the CoVent19 Challenge
Are you struggling to lead—in your business, non-profit, place of worship, or at home? Today, Host Tom Loarie talks with guest mentor Harry Kraemer Jr., who is Northwestern's Kellogg Professor of Leadership (named a favorite professor by students) and the former Chairman and CEO of Baxter International, where he worked for 23 years. Kraemer has written three books on values-based leadership. His strength, however, is not merely in knowledge and understanding of leadership, but in the ability to mentor others to lead well and to anchor all they do in the principles that matter most, putting people first. Find Show Notes here. Listen below. And sign up for our FREE podcasts—listen on any podcast platform, any time!
What is a vaccine? How long will it take to get one for COVID-19? Are there are other alternatives? What about herd immunity? Our guest is Dr. Peter Khoury, the President and CEO of Ology Bioservices Inc. He is an expert on vaccines and biologics and during his 30-year career, he has worked for the Bill & Melinda Gates Foundation, Merck, and Baxter International. Dr. Khoury has involved in international forums on vaccines, pandemic planning, and biodefense preparation. TRANSCRIPT: Intro: 0:01 Inventors and their inventions. Welcome to Radio Cade the podcast from the Cade Museum for Creativity and Invention in Gainesville, Florida. The museum is named after James Robert Cade, who invented Gatorade in 1965. My name is Richard Miles. We’ll introduce you to inventors and the things that motivate them, we’ll learn about their personal stories, how their inventions work and how their ideas get from the laboratory to the marketplace. James Di Virgilio: 0:37 Welcome to another special edition of radio Cade. I’m your host James Di Virgilio. Today we’ll be discussing vaccinations and COVID-19, there’s a lot of information, misinformation questions that you have that we have. And with us today, we have an expert in the subject of not only vaccinations, but also manufacturing them. Dr. Peter Khoury. He is the president and CEO of Ology Bioservices Inc and that is located in Alachua, Florida. He’s been involved with vaccines and biologics for a majority of the 30 year career employed by organizations, such as the Bill and Melinda Gates foundation, Merck and Company and Baxter international. Dr. Khoury has been an invited speaker for many international forums concerning vaccines. Pandemic planning, biodefense preparation, and has worked on global threat programs against biologics with many ministries of health and oversight committees for large events, such as the Olympic committee. Dr. Khoury, thank you so much for joining us today. Dr. Peter Khoury: 1:34 Thank you for inviting me. James Di Virgilio: 1:35 So the role now that you and Ology are playing in the COVID-19 crisis is essentially to manufacture vaccinations amongst other things which are going to unpack, but it seems prudent to start with asking a simple question, but one that is now talked about a lot. What is a vaccine? Dr. Peter Khoury: 1:54 Probably the simplest answer is a vaccine is a protein that stimulates your immune system to induce immunity or induce antibodies. It’s exactly as if you were exposed to the disease. So when a healthcare worker gives a vaccination, they’re exposing your immune system to something that looks very similar to a particular virus or bacteria, which helps your immune system then react quickly when you’re exposed to the real infection, it has, what’s called immune memory and it remembers, ah , I’ve seen this before and it starts immediately in a sense, producing these antibodies to fight that infection. James Di Virgilio: 2:46 Now , these viruses, I’m a big fan of game theory are essentially alive in a sense, right? They’re adapting, they’re changing and your body’s doing the same. So if you get a good vaccine and it produces the proper, it’s possible that the virus then counters that with a different response of sorts, right? Depending on what we’re looking at, Dr. Peter Khoury: 3:06 It’s amazing that a virus can be that smart, that it quickly can adapt, or it’s in a sense survivor of the fittest. It’s just like an antibiotic. When you have antibiotic resistant organisms, let’s say you have a hundred bacteria and you put an antibiotic on it. It kills 99 of them, but there’s one that has a genetic sequence that makes that a little more difficult to kill. And if you don’t take the full 10 days of the antibiotics, that one tends to still live a little bit and start rowing . And all of a sudden you’ve got a big colony of this that is intermediately resistant. And then you take another dose of antibiotics for another 10 days, but only take five days of it. And you think it’s gone away out of those hundred. There’s one that’s now resistant. So it’s surprising how bacteria or virus can quickly adapt. It’s a numbers game is really what it is. There’s genetic mutations that will cause one of those virus to have mutated enough that it’s getting around your immune system in there for it’s called drifting and shifting when it does that. And you see that with influenza in a sense every year. And it’s a big guessing game on which strains of flu are included in the flu vaccine every year. If you’re lucky, you end up targeting a protein in the vaccine that does not mutate, and then you’re golden , you don’t have to worry about. James Di Virgilio: 4:42 And that’s a lot of what’s going on right now with COVID-19. So on one hand, you read articles, we’ve found the sequencing, we know what’s going on. And then on the other hand you read yet, but that’s really a small portion of the battle. We don’t know how it’s going to react when it’s put into live testing with human patients and subjects. When we’re talking about vaccinations, how successful against a novel virus like this one, which I believe shares a genome with SARS one to a large extent, but how successful are we? Once we identify step one, this is what it looks like and is at getting it to actually work in people. Dr. Peter Khoury: 5:17 That’s a great question. We are very fortunate as it seems that this Corona viruses not doing any real shifting or drifting at all, and you are correct. So the SARS and mirrors virus, so the sudden acute respiratory syndrome in the Mideast respiratory system viruses were also Corona viruses, which are a, I think it’s a genus or a species of virus themselves. And this is just another one. Now this one, for some reason, the human to human transmission has really taken off. And that’s why we’ve now see this pandemic. And they watch this pandemic cascade around the world. If there were this shifting or drifting, they’d be able to take samples from different areas and find out when they run a DNA gels, that there has been some changes in the sequences, but they’re not seeing that at all. So that’s very fortunate that we don’t see up that allows them vaccine R and D personnel to try many different approaches to developing a vaccine. And the most common youth approaches in the past were what they called an inactivated vaccine or killed vaccine, which they take it and they either irradiated or they chemically treat it till it’s killed. And then they inject it into you and your body will develop antibodies against that, or what’s called a live attenuated vaccine, which they select specifically for a strain of that virus that when you’re infected with it, you get what’s called a subclinical infection. You develop antibodies, but for some reason you don’t end up getting the fever and the respiratory problems and all of that. Instead, you just sorta produce the antibodies for it. And so those are widely used, but there are now some very complicated ways of addressing tough issues with vaccines. HIV for example, that’s been around since early eighties and still, there’s not a vaccine available for that. I always look at that as the big mystery for developing a vaccine, we were awarded a contract for what’s called a DNA vaccine, and this was with a company called Anovo. And this is one of those very complex approaches, which we feel very confident will work, where they take a piece of DNA that codes for what’s called a spike protein. They put it in a plasmid in, this is then put in a syringe and injected using a special type of what’s called electroporation, where it opens up your cell to take in this little piece of DNA in this circle called a plasmid and it uses your own cellular system to make the protein. So your body starts producing this protein, some of your cells do. And then your other cells that normally produce antibody will see this protein being made and start producing antibody against it. So it’s a unique approach. It can be done very quickly and low cost, and that seem important thing. And one of the reasons why this approach is being looked at. James Di Virgilio: 8:41 Now, how often would this type of approach be used and things people are familiar with vaccinations for like an influenza. And , and if you don’t know anything about vaccines and you’re more like me, like you mentioned, there’s like seven or eight or nine or 10 different types. There’s different ways you can create a vaccine. This is one of them. How often has this been used successfully in other. Dr. Peter Khoury: 9:02 So it’s very novel. I don’t know of a DNA vaccine yet that has been put on the market because it’s such a new approach. And in fact, if you look at all the vaccines that have been available for the last 30 years, all of them basically fit into five different approaches. The two that I had mentioned, and then there’s conjugation. There’s, polysaccharide, there’s another one that is escaping me just basically four or five different ways that vaccines are currently manufactured. So some of the ones that people are talking about now are these very novel biotech approaches that appear to be safer, faster, lower cost, ways of vaccinating. So I’m excited that this innovations finally being used and may produce a vaccine that is both affordable, can be produced in large quantity and available may be sooner than some of the older methods used. James Di Virgilio: 10:04 And let’s unpack some of that because if we were to find using a traditional method, the actual vaccine that works, we have to go through these different phases. So step one, we’re going to start with maybe animal testing or something similar. I know chicken eggs tends to be a big one with a lot of things, but you can’t do that with coronavirus. So that’s a problem that doesn’t work. And then I know that in only 16% of the cases, do you make it from phase one to phase three, with a working vaccine? And then how often does your vaccine work? It might only work 50% of the time. And is that good enough? Right? So you have all these hurdles to overcome. That’s why it takes a long time. 18 months tends to be the soonest. People think it can happen. How different is that with your solution potentially. Dr. Peter Khoury: 10:44 So ours also about 18 months, just the clinical study. So not talking about the preclinical animal studies, but when you actually get to the point where you’re starting to inject it in humans, it’s usually between six and eight years to get through the phase one, two and three. So phase one normally is just a very small study with a few adults to make sure that it’s safe. And they do some where they look at the effectiveness on those few people. And if no one kills over in a sense, or they’re getting some kind of immune response and there’s at least something that they can measure, they’ll go into phase two, which is larger, maybe a couple hundred people in some of those are age appropriate. Then. So if they’re trying to go down to infants, they’ll then throw in a few infants into that study and they’ll do, what’s called a dose ranging study and look at what’s the optimal dose that you would use for them. And they really start looking at the side effects and other things cause they have a larger pool to draw from once that’s through and they get the go ahead to go on to phase three, they go into this much larger trial than some of these, especially with infants can be tens of thousands because they’re trained to pick up the background noise, a very small number of crucial side effects that potentially could happen. And they’re taking very detailed measurements of how safe and effective it could be. Once it gets to that, it goes in front of the FDA. It gets approval for use or rejected, but usually by then, they’ve spent hundreds of millions of dollars. Hopefully it gets approved, but even then many companies commit to what’s called a phase four study, which is a post-marketing commitment to follow up with people that have been vaccinated and also submit to the FDA. Anytime there’s adverse events, send them information. So they keep track of it also. So it’s very useful. I’ve got to say for every vaccine that goes through, there’s probably 50 that don’t make it to the market. So there’s a lot of money spent on R and D. Our government’s been very good at funding, quite a bit of novel R and D, which has been great. Healthcare is expensive. There’s no doubt. We’re one of the few countries that really support innovative research and development. And I hope that people still continue to do that. I think that any shorter than a year and a half to do those studies, you would have to do it on what’s called a patient name basis where people would have to sign a form and say, I understand it hasn’t been fully tested, but I’m willing to take it untested because the risk benefit ratio to me is such that I’m willing to take on that risk. James Di Virgilio: 13:39 And that’s something like Ebola, right? When Ebola came out, people were saying, well, we can’t even have a control study because nobody wants to placebo. Just give me a chance with this vaccine versus letting this run its course, which creates difficulty in developing a vaccine. How often are these vaccine side effects worse than what we’re dealing with? Is that something that’s frequent or is it pretty unlikely that even a testing vaccine is worse than what someone would already have? Dr. Peter Khoury: 14:04 That’s a great question too. The only one that I can think of that they had some problems with. And if you go back and look at the data in hindsight, they had overreacted. Some was with the original Rotavirus vaccine, which is a terrible issue. It’s a diarrheal disease that infants get. And when they first did the studies, the studies looked fine, but it wasn’t picking up these incidents of what’s called intussusception, which is when the intestines fold in on themselves. And once they started using it widely around the United States, within the first two or three months, I had all these infants die of this intussusception they immediately pulled the vaccine from the market. People were in an uproar, but more children died of Rotavirus. And another great example is when you look at polio vaccine, so polio, which still hasn’t been eradicated, there’s still a few places around the world that have polio. They were using oral polio vaccine for years, but in one, in a million cases, when a child gets oral polio vaccine, it converts back into wild type polio. And the child actually ends up getting polio. So one in a million children end up getting polio from the vaccine, but the other 999,999 children are all protected and fine, but they were so upset about that one child that a lot of money has been spent to develop alternate vaccines for polio. James Di Virgilio: 15:41 Yeah. I find that to be interesting. And I’m really glad we’re talking about this now, because to me, everything in life is a risk reward continuum. It’s very rare that you get a very pure two. Plus two is four here all the time. This is the obvious decision. Most often, it’s that sort of decision. Well, if we do nothing, we have this. And if we do something it’s possible that we have this side effect, we don’t know, but what is better than starting with our baseline. And that’s a really good contextual answer. So it sounds like the majority of vaccines are not generally super risky, worse than what we’re trying to fix, but maybe they’re not as effective as others. So if I’m a company, big pharma or otherwise, and I want to manufacture this, right, we have the lab that discovers the vaccine. They come to me and they say, James, we want you to manufacture this. How likely am I to take this on? Because the numbers seem very low. It seems likely I’m going to lose a lot of money and not all of these outbreaks we’re dealing with. Come back again. So maybe I develop a vaccine and now it’s sort of just gone. How likely is it for companies to want to fund these initiatives? Dr. Peter Khoury: 16:39 That also was a great question because all we know right now is that we’re having a pandemic and we’re not clear whether it’s flattened out or not personally, I don’t think it has yet. And I think still may be the worst is yet to come. And I hope it doesn’t act like a influenza, a pandemic where you get a small wave. And then a few months later, maybe this fall or a little later, you get a much larger wave that travels around the world and will kill hundreds of millions instead of a million or two. So I’m just hoping this does not happen or that it takes on the route that influenza does where it’s North hemisphere for half the year, then goes down to the Southern hemisphere, then swings back up to the North. They’re not quite sure because we haven’t had the experience yet with this Corona virus. What they do now is it’s not like SARS. It’s not like MERS where it was here for a few months and then suddenly just sort of disappeared. This just seems to be staying. So with that, the question is, will it become a yearly vaccine for people. Will there eventually be some drifting of it. So they’ll have to be a new vaccine every year. How profitable will it be for companies? Will companies start looking at other emerging infectious diseases and start the research and development earlier, or will the government fund that early research and development? Because there are emerging infectious diseases around the world that we don’t have in the United States, but make some background noises in other areas that could easily be the next coronavirus . So when do you start investing in that? So you’re a year ahead of where you are now. James Di Virgilio: 18:32 And that’s a great topical point to discuss. You mentioned something earlier about research being done, and I’m not sure how many people know this, but the medical research done in the US and innovative work like you’re mentioning is a hundred times or whatever the number is. It’s so significantly more than anywhere else in the world. If you look at that graph, it’s the US and everyone else is tiny. I think Germany is second on that. And their infinitesimal compared to what’s done here. There’s a lot of negative emotions around what big pharma and other stuff does. And we’re not going to get into that. Other than to say that it is a fact that so many dollars in this country go towards trying to solve these problems. And then here we are with things that are unpredictable to a certain end. Now you worked for what maybe now has become the most famous right kind of foundation. There is with the Bill and Melinda Gates foundation, looking at trying to solve this problem. Bill Gates has been beating this drum for a long time. This is the biggest threat to humanity. What you just mentioned was sort of getting ahead of this. Is there a way for us, was there a way for us, will there be a way for us to sort of prescriptively try to get ahead of some of these things you just mentioned, things that are bubbling up elsewhere, we know kind of exist. How do we do that? Dr. Peter Khoury: 19:34 So there actually is a list that is kept by the government. The CDC has one, the world health organization has one . If you go on their websites, they talk about emerging infectious diseases. And in fact, the Gates foundation has an area that focuses on these emerging infectious diseases also. And so people do keep tabs on those large pharma, looks at them and says, there’s no value to us because we lose money, investing on things that we think are going to be valuable, but it’s just hard to solve the problem. You think of the billions of dollars that have been spent on HIV vaccine instill of course one is not available. So they think about that, but then they look at something that’s just emerging, especially if it’s in the developing world, they say, it’s just not worth that someone else should fund it. Gates foundation, fortunately does, which is great. The welcome trust is another, that does. So there are some that do that funding. The US government will fund some of them. If they feel that there may be a threat of it, either coming to the US especially some of the vector diseases that are transmitted through ticks or through mosquitoes, or could be used in biodefense, which is another area that people don’t pay that much attention to. We remember the anthrax scare and what happened. Then that’s another area that I think probably needs more focus from all governments. So both pandemic planning for other things than just influenza in also good preparation for biodefense. James Di Virgilio: 21:17 And there’s this interesting thing. When you think about humanity, that always strikes me. I’m an investor professionally, and with investing, nothing is black and white. It’s a lot of study of people and behavior and things that we know to be true. And one thing that is definitely true is we’re not very good at predicting anything as humans. In fact, we’re the most accurate at predicting the weather and we can go about 48 hours before that falls off a cliff of actually being significant statistically. So when it comes to these really complicated problems, I often think of the three body problem. You can know A, and you can know B and you can know everything about factor A and factor B, but you can’t know C you just can’t know where it is. And I think people sometimes pale to understand how complicated and chaotic these systems are. And just because we know A, and B does not mean that we can ever predict C, it’s not easy. It’s not simple. It’s not a one week or one month process. And even with our best foresight efforts, we may never get the prediction. Correct. And then there goes a lot of money into something that may yield nothing, right? And you’re kind of always doing this where, like you mentioned, do I put my dollar? So now that we’re facing COVID-19 and actively, we know we need to solve this problem. The engines are running, the creativity is going, innovation is happening. You are mentioning something that’s brand new right now with regards to trying to save this. And then there are also some other techniques out there. Tell me about using plasma from recovering patients to protect the most seriously ill what’s going on with that. Dr. Peter Khoury: 22:41 Yea I know that that has been on the news and it is an effective way of treating. So what they do is they take convalescent plasma from patients that have recovered, because it has antibodies in it. And those include antibodies that protect against COVID-19. And it’s a fast way of developing. What’s referred to as hyper immune state, where you have more antibodies than normally your body would produce. So they take the most ill people in, they’ll put in this convalescent plasma, which they know contains these antibodies while they contain a lot of antibodies and other things. But for sure it contains the antibodies that help that person recover from COVID-19 and it boosts their immune system of the target patient. That downside is the possibility of their body in a sense rejecting it, it can cause a negative immune response due to something in that plasma or in this has happened in the past a yet to be identified foreign item, which could cause issues to recipients later on. And that’s with anything that’s blood related. I mean, we saw it with HIV at the very beginning where people were getting blood transfusions, you saw with it mad cow disease at times where prions were transmitted through blood transfusions, but there is another solution. And actually we’re working on it. We were given a grant to work with the Vanderbilt University medical center to produce what’s called a monoclonal antibody. So what they do is they take the antibodies from a convalescent patient, and they’re able to find out which specific antibody is the one that works the best. And they clone only select for the cell or the piece of DNA that produces that protein, that codes for that antibody. And they’re able to replicate that in produce just that one antibody, and you can do it in big fermentors or bio-reactors. And you produce these monoclonal antibodies, which are all exactly the same and mass produced . Those had a fairly low cost that can be much faster than vaccines. Now you may see monoclonals before the end of the year, and those most likely will go to healthcare professionals, those immediately on the frontline for protection, and also those that are most critically ill would get these monoclonal antibodies. Those will definitely be lifesavers. And I suspect that the first will be out quite a bit before the vaccine will be, James Di Virgilio: 25:30 That’s like a triage solution, but not the best longterm. Is that a three ? Dr. Peter Khoury: 25:35 Yeah. It’s not long term because eventually your body will remove those antibodies. So you’re talking a few weeks protection when you’re talking a vaccine, you’re talking usually a much longer term protection of years, if not the rest of your life, sometimes vaccines. If they elicit a longterm immune response, you only get them once. And that’s that you’re protected the rest of your life. James Di Virgilio: 25:59 So the way out of this is seemingly to have a vaccine. That’s what people are saying. Dr. Peter Khoury: 26:03 It is. James Di Virgilio: 26:03 The world’s not going to truly relax into, we have a vaccine or this just maybe mysteriously disappears, which seems very unlikely at this point. Dr. Peter Khoury: 26:10 Right? And even if it disappeared, there’s always the chance of it coming back. The same with SARS , the same with MERS. I mean, all of those could somehow reappear. James Di Virgilio: 26:23 So we need to get a vaccine. We know that it takes a long time to actually manufacture a vaccine because it’s not that simple. It’s not like we have all the supply available in the world to produce a vaccine. We can’t just in a day, produce enough to give to the whole world. Right. So even when we get it right, it takes a while to actually produce enough to give out to all the people that need these vaccines. Here we are in the US in a country that has all of these resources. What if we’re not in the U S what if we’re in a developing country? What does it look like for them? Dr. Peter Khoury: 26:49 Yeah. So in the US yeah, we’re fortunate. We have a lot of vaccine manufacturers, large manufacturers here, and in the time of pandemic borders closed down. And so if you don’t have vaccine manufacturing on your soil, it can be a real issue. That’s times where the, WHO, UNICEF the large manufacturers get together and say, we need to do something for the developing world. And they actually will donate vaccines that are used in those areas. I know of some manufacturing processes, and we actually in our building bring in some of these new types of manufacturing, just on a trial basis. And some of them are small enough that they literally could be put in a shipping container and take into areas where vaccine needs to be produced immediately. But then you run into problems with clean water and power and other things. But someone has taken the first step to develop a concept of manufacturing that now whether you can get a turn on solar power and you ship in water, where that, or you make the manufacturing process somehow different, I think eventually they’ll have something that is a vaccine in a box that you could ship to these countries that will produce low cost vaccine very quickly. The smartest thing right now is to stockpile vaccine. If you can, if you’re a country and you have the wealth to do it, and you don’t have vaccine manufacturing, if there’s a chance for like the release of smallpox , for something as a bio threat, you may want to stock pile some of that vaccine, because if it ever happened, you’re going to wish you had. James Di Virgilio: 28:44 Right. I have something there. So herd immunity is talked about a lot, right? I’ve seen that we need maybe 50 to 60% of the population to have herd immunity. And it seems like there’s a lot of misconceptions starting with the UK, which that was their original strategy. Then they kind of shifted away from it. Now, maybe going to go back to selective release, to build herd immunity, assuming that this goes more of the route of HIV for a little bit, it takes longer than 18 months to get a vaccine, or are we able to build herd immunity without a vaccine? Or is this something where we would just continually have recurring outbreaks of the same significant level year after year? Dr. Peter Khoury: 29:21 It depends on what the virus does. If the virus goes away, you’ll never develop herd immunity. Just the people that happened to come down with it . The same with SARS. I’m curious if someone had SARS, are they immune to this Corona virus? That’d be interesting. I’m sure someone’s looked at it because there may be some cross reactivity, the two, but eventually enough people would be infected and recovered that you’d reach that 50 or 60% mark. And then it’s again, a game of numbers where the virus no longer is transmitted rampantly through the population. And so exposure risk goes down dramatically. When you reach that. The other approach, when you do have vaccines or monoclonal antibodies, is you do ring vaccination, where you find an area where people are infected and around it, you vaccinate everyone in the area. And so it’s contained. And that actually has been shown to work very, very well. Now, if in Wu Han, they had identified and raise their hand very early and put something in place where they either stop the movement of people within that area, which is probably all they could do. Then it probably could have been restricted much, much more, or if there was a vaccine available, vaccinating everyone around the city and making sure people didn’t move out until they were over it. James Di Virgilio: 30:49 Right. And that’s the key is stopping the transmission. If we have five people that are immune, got a vaccine there, then all of a sudden you have the one sick person, the virus can’t get passed on, which is obviously the goal. So let’s spend just a few minutes talking about something that maybe is been confused or is confusing. Are we flattening the curve, therefore reducing the total number of people that will get this, or are we just shifting the total number of people to get this to a lower monthly average? So basically same total are going to get it regardless, but we’re just spreading it out. Dr. Peter Khoury: 31:19 See we never know again, because we don’t know if the virus will just dissipate and disappear. If it doesn’t then as you lower the curve, you’re maybe spreading it out. But when you spread it out like that, the vaccine comes out a year and a half later, then there’s a lot of people that still can be vaccinated that haven’t had it. And so there’s a much lower risk that they’re going to get it and then die, or have significant morbidity in mortality from the actual disease itself. So flattening the curve helps in two ways. One is if the virus stops circulating, more people were suffered the consequences of having the disease. The other is if it continues to circulate, you’re buying yourself time to get something that could, in a sense, truncate people getting sick, which would be the vaccine in this case, James Di Virgilio: 32:14 Is there a consideration to extreme flattening of the curve, which we know will potentially lead to more people, not getting it in the short term, but with the other side, which is how much damage do you do to society. And there seems to be two effects. We have Spanish influenza where most cities did nothing, and they took the full brunt of that peak, heavy hits, 50 million die. And then you have what we’re doing now, which is the first world’s response to really do exactly what you just said. Is there a balance and consideration as a medical person, do you think of what do we do over here economically, if everyone loses their job for a year, or is there just, this is the way we have to do it in order to reduce these cases? Dr. Peter Khoury: 32:51 That’s a real difficult one because as I look around me and I see the unemployment rates skyrocket 10%, 10% last night, I was listening to the news and I just couldn’t believe that it’s gone up so much and that’s just in the US let alone other countries. And I think it’s going to definitely cause a global bump, how quickly we recover from that. I think we’re pretty wrestling and the whole world will recover, but all of the ships are going down at the same time. So the question is, how much impact does it really have on the economy? If the whole globe is shrinking, if everyone’s economies being hit by the same thing. And that’s the part I don’t understand is it could be a lot worse if it were just the US and everyone else was still thriving. That probably would be even worse for us. But when everyone’s going through the same hurt, it’s still bad. There’s no doubt about it because production’s down. People just don’t feel like they’re productive, which is also a mindset thing. It’s, it’s not good for anyone. That’s a real tough question to ask, but there is a trade off there. There’s no doubt about it. And if there were a way to protect everyone and they could go to work, and we knew that they stopped shaking hands and everyone stayed exactly six feet away from each other, eventually the virus would go away. James Di Virgilio: 34:20 And I think that’s, what’s interesting is we tend to look at these things in static environments, but the reality is every day we’re learning more. And , and even though we know that maybe there could be, like you said, a rebound in the fall, everything we’re learning every day helps to apply how we might return to normalcy. And I think one thing I’ve really learned is that we respond very well as humans. We’re not good predictors. We’re excellent responders. We’re very creative. We’re great problem solvers, but we have to have the problem in front of us, which we now have. And like you mentioned, I think the doomsday scenarios of us flattening the curve and no one doing anything for months is probably unrealistic because there will be some tactical solutions to get people back. Bill Gates, himself, I saw just said, I think a day or two ago that the global economic reaction to this will not be immediate recovery. This will take time, which I think he’s totally correct. And there’s also something else that I think has gotten lost in this, whether the government should have reacted faster or slower or whatever the case may be. Some things in life are beyond our grasp to understand right away, could China to something earlier. Absolutely, will that hopefully be a model for the world later? Yes, but we don’t have a clear solution forward. Like you mentioned, we hope that we’re thinking of the trade offs. If I choose this course of action, hopefully I won’t bankrupt the whole world, but if I don’t choose that course of action, how many more people get it right now? Can we handle every, all these questions? They’re very difficult to answer. And so I think day by day is the course to say, what’s the new data say, what are we doing? And ultimately, when it comes to a vaccination, is it helpful to have more testing at all? Or do we already have all that we need on the vaccination front to get all that research done? Testing is irrelevant to actually developing a vaccine. Dr. Peter Khoury: 35:51 I think testing is very important. There’s no doubt about it, but how much of it can be done concomitantly with administering it to people that are at high risk, let’s say so that’s when you get into that whole risk benefit again. So the very first people in the phase one and two, should they be the emergency room workers cause you now, Hey, if it works, that’s great for them. If it doesn’t work, maybe a few will have some issues, but there’s a chance that it’s going to work because some of these are pretty tried and true methods. It’s a real trade off. And it all comes down to that risk and benefit. People tend to like pointing their fingers at the FDA, but the FDA has a job of keeping people safe. And when you’re administering in our country, over 300 million doses of this, they give a vaccine to every person in the country. That’s a lot of people, that’s a lot of lives that you’re taking responsibility for, but there is an urgency to , so again, there it’s that whole risk benefit. James Di Virgilio: 36:55 Right? And I tend to be someone who thinks central governing organizations are slow and inefficient in general. Because again, it’s hard for us to prescriptively know what’s going on, but in times like these there’s things that I think are being done well, which the FDA has greatly relaxed the hurdles that exist to create a vaccine. So no matter how you feel about the FDA, if you’re more like me, the things I’d like to see it be a little more expedited in times it’s happening now. And in fact, I think it’s safe to say, if we just got rid of the FDA right now, it sounds like the vaccination time wouldn’t be any faster than 18 months at this point in time. Or if it was, it wouldn’t be significantly more, right ? So we can take that off the table. The FDA is not going to materially affect the speed with which we’re creating a vaccine for COVID-19, which is a good thing to get out there. All right . This has been a wonderful wide ranging expert discussion on vaccinations. Certainly we applaud Ology for doing something that’s brand new, which is really neat, right? This DNA vaccination. We look forward to hearing more about this as we go on to conclude the podcast. Is there anything that we haven’t talked about yet that you feel is something you’d like to discuss? Dr. Peter Khoury: 37:57 I feel like I’m the most fortunate CEO in the world. I lead a company that is still privately held and with a large majority of our shareholders that are current or past employees. So many of them are really dedicated individuals. It really see the value that we bring to the market, not just bottom line profits. It allows us to truly support programs where we can combine the measurement of profitability and potential life saved to what Gates foundation does when we decide I’m bringing in new work. So I mentioned that we do work with the government and we do a lot of commercial work with everything from small laboratories to large multinationals. But we also do work for NGLs is like the Gates foundation and others. That really is not all that profitable. And I know that these doses are going to developing world countries and whatever, but my team who, as I said, are everyone that joined their company is given options for shares. The first day they joined, because I believe that if they’re invested in the company, that they will always do the right thing, they’ll always raise their hand when there’s an issue. And they’ll make sure that we have the best quality and we’re the safest. And they’re the ones that agreed that they don’t mind taking a little less money if we’re helping to save lives in doing so. So I’m still proud of them in taking that mindset on it. It’s a lot of the younger, what I’d call millennials, the younger crowd that really likes that. And when we bring in new programs, we have to sit everyone down and explain to them exactly what it is and how it’s used and what the diseases and how many people died , because they want to understand exactly how they’re helping the world and God bless them for doing it. James Di Virgilio: 39:58 Yeah. Love your neighbor as yourself. Right. And there’s a lot of that going on now, there’s one silver lining to something like COVID-19, it does bring the world together and makes you recognize there’s really no such thing as race or gender difference or things like that. Because at the end of the day, we’re a human race and we’re all people and this virus doesn’t care. It doesn’t at all about the fact that you’re a different color from someone else that does care that you are human. And like you mentioned, we can care for our neighbors. We can care for those that have less resources than we have. And we should use that if we have the ability to assist. And the culture at your company obviously is doing that from day one, which will I’m sure leads you to better results in the long run. Anyway. Dr. Peter Khoury: 40:34 It, will I’m sure. Thank you. James Di Virgilio: 40:36 Dr. Peter Khoury. Thank you so much for joining us. This has been absolutely fantastic. We’ve certainly enjoyed visiting with you and for Radio Cade. I’m James Di Virgilio. Outro: 40:45 Radio Cade is produced by the Cade Museum for Creativity and Invention located in Gainesville, Florida. This podcast episodes host was James Di Virgilio and Ellie Thom coordinates, inventor interviews, podcasts are recorded at Heartwood Soundstage, and edited and mixed by Bob McPeak. The Radio Cade theme song was produced and performed by Tracy Collins and features violinist, Jacob Lawson.
What is a vaccine? How long will it take to get one for COVID-19? Are there are other alternatives? What about herd immunity? Our guest is Dr. Peter Khoury, the President and CEO of Ology Bioservices Inc. He is an expert on vaccines and biologics and during his 30-year career, he has worked for the Bill & Melinda Gates Foundation, Merck, and Baxter International. Dr. Khoury has involved in international forums on vaccines, pandemic planning, and biodefense preparation.
Stock Stories | Case Studies and Mental Models for Individual Investors
Baxter International is one of the world's largest healthcare companies. Their products can be found in hospitals, nursing homes, clinics, and doctor's offices around the world. They invented a safe storage method for blood as well as the first artificial kidney, so there is a long history of innovation. In addition to Baxter's past, we also look at how we expect it to perform as an investment in the future. --- alex@stockstoryteller.com Instagram: stockstoryteller
The Dow closed down 19 points, and Jim Cramer’s making sense of today’s headlines. Then, after reporting a strong quarter Zebra Technologies rallied nearly 7% today, but could the stock have more room to run? Cramer’s checking in with the CEO. And, after earnings Twitter has fallen from the sky, but could this bird earn its wings back? Cramer’s sharing if the recent dip presents a buying opportunity or whether you should stay away. Plus, what should you make of Baxter International’s post-earnings decline? Cramer’s breaking down a key piece of information that should impact your strategy when dealing with the stock. Learn more about your ad choices. Visit megaphone.fm/adchoices
Christian Perez Font is the founder of Thinkeen Legal, a law firm that uniquely incorporates data analytics, compliance and law. He began his career as a corporate attorney and in 2008 joined Baxter International, a multinational healthcare company, as in-house counsel. When he joined Baxter, his work was 10% compliance-related and 90% business-related, but by the time he left 5 years later, he was doing 65% compliance work. The key to becoming a better compliance professional, he proposes, is to become a better business person. He and host Tom Fox discuss the importance of data in compliance and in business. Data as Fuel When people think about Data Analytics they imagine some form of AI that's going to automatically pinpoint problems. Christian says that the truth is that Data Analytics has to be at the core of compliance: data is the fuel that powers the compliance engine. It’s the data that will tell you how you should be communicating compliance policies and doing training so that you can achieve your business goals. Most of the data that is used for compliance purposes is already there from the business side; you just need to understand how to aggregate it, how to look for it and how to plug it in. You have to understand your industry and your company goals before you start collecting that data. How Thinkeen Uses Data Tom asks how Thinkeen Legal uses its data proficiency in mergers and acquisitions, transactional work and compliance. Christian shares how his company used its data expertise to advise clients in cross border transactions. Because we know where the touch points are, he says, we’re able to incorporate them into the due diligence process and ask the right questions and get the right information. They can identify areas of risk which helps their clients decide whether to proceed with an acquisition. Christian finds that general counsels are becoming more savvy about compliance and they appreciate that his firm gives them advice and support. The Future of Data and Compliance The intersection of law, data and compliance will continue to evolve, Christian predicts. He is happy that the importance of Data Analytics is being acknowledged. If you don’t have the right data, you won’t get the right information, without which you can’t make the best business decisions. In addition, a big part of what we do with data is benchmarking, Christian says. The more information that we can share among the industry, the better. Resources ThinkeenLegal.com Thinkeen Legal on Twitter | Instagram Christian Perez Font on LinkedIn Learn more about your ad choices. Visit megaphone.fm/adchoices
Open communication and high performing teams don’t just appear out of nowhere. In order to have a team that gels, you need to put in the work to create a space in which all team members know the vision of your company, have clear expectations, and know how to course-correct when things go awry.Eric Foster, a CIO with experience spanning multiple technology firms sat down to speak with Pat and Shelli on his three-part framework for creating high performing teams. Eric also explains why it is so important that you spend time thinking about the culture you want and how to go about creating it. Listen in for tips and book recommendations so you have the tools you need to create an unstoppable team.[00:23] - This week: Eric Foster[01:25] - Individual all-stars or a high performance team: Reflecting on the 2004 US Olympic Basketball team[03:06] - 3-part framework for improving team effectiveness:[04:26] - Clarity[06:00] - Accountability[07:08] - Course correction[09:34] - Integrating external resources[15:16] - Building high-trust environments[21:00] - Creating a strong culture[27:38] - Building trust as a leader[28:32] - Retaining great people[29:32] - The Leadership Cube for aspiring leaders[32:15] - Serving the organization Eric Foster has been a technology executive in a variety of industries, including Distribution, BioPharmaceuticals, Medical Products, Advertising and Financial Services. He has been CIO for two Fortune 500 companies, Univar and Baxalta, and has served in IT leadership positions at Baxter International and Heller Financial, as well as CTO for Publicis Groupe. He started his career in consulting at Andersen Consulting (now Accenture). He has a bachelor’s degree in Aeronautical and Astronautical Engineering from the University of Illinois.If you'd like to receive new episodes as they're published, please subscribe to Innovation and the Digital Enterprise Insider in Apple Podcasts, Google Podcasts, Spotify or wherever you get your podcasts. If you enjoyed this episode, please consider leaving a review in Apple Podcasts. It really helps others find the show.This podcast episode was produced by Dante32.
In 2001, Harry Kraemer faced a full-blown leadership crisis. At the time, he was CEO of healthcare company Baxter International. When one of his company's products was linked to patient deaths worldwide, it was up to Kraemer to decide how to respond. On this episode of the Kellogg Insight podcast, Kraemer discusses how to make hard choices that align with your internal compass.
Lance Scoular Show Notes Lance Scoular, AKA The Savvy Navigator, has been involved in International Trade and Transport for 50 years; In 2008, Lance started receiving invitations from students in his classes to connect with them on both Facebook and LinkedIn. Over the last nine years, he has developed and expanded his social media networks exponentially (especially LinkedIn, Twitter, YouTube, Snapchat, and beBee) and those of a select group of clients in a variety of sectors, both locally and globally. The results have been significant. Lance is now in the process of doing a 180-degree business pivot, refocussing away from Social Media Consulting, back to what he does best, International Trade and Transport Training. He is soon to launch an online course “Import Export Made Easy” in video and audio as well as the “Import Export Made Easy” Podcast. Lance’s career I started my business back in the early 1970s as a shipping supervisor in what is now known as Baxter International, a fortune 500 company. In 1976, I completed my studies at TAFE, which is the Technical And Further Education College in Australia, and I passed the exams of the Australian customs services. I took two weeks holiday from the company I was working in to door-knock local businesses in my area to see if I could find people who were dealing with exporting and importing that are interested in my services. I gained a few clients and resigned from the company. Most of my marketing was door knocking, and I used direct mail, and telemarketing with the Australian Yellow Pages. Import-Export is a very big deal in Australia. Most passionate about Today, I’m pivoting. Back in 2009, I got very involved in social media. I was running an Import Export course, and I was getting invitations from my students to connect with them on Facebook and LinkedIn. In the beginning, I didn’t understand what they wanted from me, but once I Googled it, I got very interested in the business potential of these social networks. As we mentioned before, Australia was very isolated from the rest of the world, the Internet and social media, in particular, have changed that. In 2009, I decided to start helping people to use social media with no connection to import or export. (I still taught the import and export courses, but the number of courses dropped during those years.) And today, I’m pivoting since I just recently realized that I could help many businesses all over the world with my knowledge and expertise in Import and Export, so I’m about to launch my first online Import-Export course. The exciting thing is that I’m going to use my wide network of social media connections that I built over the last nine years to promote my course. Lance’s best advice about approaching customers The definition of a customer back in the 70s was someone who buys goods or services. I came across a marketing strategist, Sean D’Souza who wrote a book called, The Brain Audit, about why customers buy, and in that book, he talked about his concept of a client. He relates to Webster Dictionary which says, ‘If you are a service provider, the client is someone you should care for, someone who comes under your protection, and someone you should guide.’ I believe in the concept of care, protection, and guidance for your clients. Biggest failure with a customer Well, I’ve had failures… like most of the guests in your show. It’s a learning situation. Back in 2007 and 2008, I was running my own course, but I was also asked to be a guest presenter at the Sydney Community College, two courses for young entrepreneurs. One for young people that were thinking of becoming entrepreneurs and another one for those who are already entrepreneurs. On one night, I was asked by the course’s facilitator to share one of my business stories with the entrepreneurs. Some of the entrepreneurs were doing great things, and I didn’t want to...
Hospitals across the US are struggling to maintain their supply of IV bags due to the effects of hurricane Maria, which struck Puerto Rico on September 20, 2017, crippling Baxter International's ability to manufacture the bags. Join Mike as he draws a lesson for entrepreneurs, owners, and executives from this crisis.
Baxter CEO Joe Almeida discusses the challenges of taking over the hospital-products maker, reshaping its culture, focusing its strategy for the future, and investing in its people.
Wednesday, July 12th at 1:00PM PST/84M EST our special guest on This Week in Accountable Care is Hal Sadowy, PhD, President and CEO Premier Healthcare Advisors. Per bio: Dr. Sadowy is President of Premier Healthcare Advisors, Carmel, IN a specialized healthcare consultancy. He has extensive leadership experience a CEO for a number of diverse healthcare enterprises—including physician organizations, Medicare, Medicaid and commercial health plans a major revenue cycle management company, a publicly-traded Disease Management Company and a full-service healthcare marketing company. For many years he served as the national IPA expert for Dorland. He was a hospital executive in Phoenix and California and frequent speaker for the AHA. He was an executive with IBM after working at Baxter International as head of implementation for their Disease Management Company— RMS. He also worked for Yale University as a member of the DRG workgroup and the Connecticut Medical Society as Field Director of Research. Dr. Sadowy has two MS degrees, one in public administration & city planning and the other in research and statistics. He earned his PhD from the University of Connecticut with specialty expertise in healthcare management, health economics and health law. He is the author of over 200 papers published in professional and peer-reviewed journals. He is a frequent speaker at national conferences as well as a facilitator for Board Retreats. Join Drs. Andre Berger and Alex Foxman, co-founders National ACO for an exploration of the ACO industry.
Tuesday, July 11th at 5:00PM PST/8PM EST our special guest is Hal Sadowy, PhD, President and CEOPremier Healthcare Advisors. Per bio: Dr. Sadowy is President of Premier Healthcare Advisors, Carmel, IN a specialized healthcare consultancy. He has extensive leadership experience a CEO for a number of diverse healthcare enterprises—including physician organizations, Medicare, Medicaid and commercial health plans a major revenue cycle management company, a publicly-traded Disease Management Company and a full-service healthcare marketing company. For many years he served as the national IPA expert for Dorland. He was a hospital executive in Phoenix and California and frequent speaker for the AHA. He was an executive with IBM after working at Baxter International as head of implementation for their Disease Management Company— RMS. He also worked for Yale University as a member of the DRG workgroup and the Connecticut Medical Society as Field Director of Research. Dr. Sadowy has two MS degrees, one in public administration & city planning and the other in research and statistics. He earned his PhD from the University of Connecticut with specialty expertise in healthcare management, health economics and health law. He is the author of over 200 papers published in professional and peer-reviewed journals. He is a frequent speaker at national conferences as well as a facilitator for Board Retreats. Join Drs. Andre Berger and Alex Foxman, co-founders National ACO for an exploration of the ACO industry.
Joe Almeida, CEO, President, and Chairman of Baxter International, Inc. joined Baxter at the beginning of 2016. He knew immediately the company needed an infusion of innovative spirit to begin to move forward.
Karenann Terrell has first-hand experience with the impact of women supporting women in her career that includes roles as CIO of Wal-Mart and Baxter International. Sharing stories and personal experiences, she relates how easy falling into "mean girl culture" can be and what it looks like to call it out. She also talks about shoulders - those she's been lifted by, and her own she offers to others - and why she believes in tribes of women. Then, STAY TUNED for our new segment and a special "podcast only" give-away!
Join host, Greg Carlwood, of The Higherside Chats podcast as he talks about the international scope of Pizzagate with researcher, Ryan Zimmerman. Although the idea of the elite abusing children is nothing new, the concrete evidence provided by the Pizzagate investigation has unveiled an epic organization stretching across all corners of the Earth. And while the Pizzagate saga seems to have been covered in great lengths, today's guest has spent an abundance of time researching the intricate details still left unexposed. From genetic research and kidnappings to a trifecta of evil in the form of corporations like Dyncorp, Stratfor, and Deagle, this Pizzagate 2.0 show take a deeper look into this centuries biggest scandal. 2:42 Greg begins by having Ryan retrace his path from simply being an observer, to finding himself as one of the leading investigative researchers at the forefront of exposing horrific crimes. While studying to become a MUFON investigator, Zimmerman frequently lurked Reddit. But, it wasn't until the overwhelming abundance of primary documentation involving Pizzagate hit, coupled with the concerted efforts to suppress this story, Ryan decided to act. 11:30 While the circumstances surrounding the mysterious disappearance of Madeline McCann have been connected to John and Tony Podesta, the blinding confirmation that came with the release of the Podesta emails deserves a second look. The circumstantial evidence including the close proximity of Podesta on the day of McCann's disappearance and the suspect profiles matching their description now pale in comparison to the newly circulating gene trafficking subplot involving Coloboma, otherwise known as "snake in the eye". 24:20 Moving on from the high strangeness surrounding Madeline McCann, Greg and Ryan tackle the newest development in the Pizzagate saga: the role of the private military. They discuss the role of Dyncorp in American foreign affairs and the nefarious and egregious human rights violations being committed by them, specifically in Bosnia, Iraq, and Afghanistan. 31:40 With a lot of the companies discretely connected though a tangled web of subsidiaries, unraveling this mess can be a bit confusing. Greg and Ryan discuss a Dyncorp sister company, Dynport and it's involvement with Anthrax as well as partner company, Baxter International's, involvement in the contamination of vaccines and infecting patient with Hepatitis C. 34:42 Another group in the treacherous triad is Stratfor, the "shadow C.I.A" who hold military contracts and act outside the law with absolutely no accountability. With a roster of "who's who" of pedophiles ranking in the top slots at Stratfor, a deeper investigation into characters such as George Friedman and Bayless Parsley is in need. 40:35 Capping off the unholy trinity, Greg and Ryan set their sights on Deagle. An influential intelligence company employed by the US government forecasting a gruesome and apocalyptic future for countries such as the US, Germany, UK, and Japan. 45:40 Ryan elaborates on the corrupt nexus of Dyncorp, Stratfor, and Deagle, their prevalence within the government, how the expansion of the corrupt military industrial machine has impacted national security and the stranglehold these organizations have over politicians such as Hillary Clinton. Subscribe to the plus show to hear the extended episode, including: - Dyncorp's role in artificial intelligence and satellite technologies - encrypted data found in attachments in John Podesta's emails, including a strange owl symbol and photos of Antartica - the process for researchers to access encrypted data within the Podesta emails - the link between the pedophile ring and Justice Scalia's death - the "Wet Works" email sent to Podesta and the movie script containing the map of Texas - the pedigree and connections of James Oliphant - the next threads of Ryan research - MZM and Dyncorp's link to human trafficking in...
1) Patients treated with antiepileptic drugs and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Nathan Fountain interviews Dr. John Wark and Prof. Terry O' Brien about their paper on falls and fractures in patients treated with antiepileptic drugs. Dr. Jennifer Fugate is reading our e-Pearl of the week about Duchenne muscular dystrophy. In the next part of the podcast Dr. Alberto Espay continues his interview with Drs. Titulaer and Vincent about their lecture on clinical features, treatment and outcome of 500 patients with anti-NMDA receptor encephalitis. Next week, we will continue with interviews from other plenary sessions. All participants have disclosures.Dr. Fountain serves as an editorial board member of Epilepsy Currents, serves on the Board of Directors, National Association of Epilepsy Centers, receives travel reimbursement from UCB; performs EEG interpretation for the University of Virginia (10% effort); receives research support from UCB, Sepracor Inc., Medtronic, Inc., Vertex Pharmaceuticals and NeuroPace; and is funded by the NIH.Dr. Wark serves on the scientific advisory boards for Amgen/GlaxoSmithKline, Novartis and LactoPharma; serves as a specialist editor of Clinical Science; editorial board members of Osteoporosis International and Journal of Osteoporosis; serves on the speakers' bureau of Servier, Amgen, Novartis, Sanofi-aventis, Eli Lilly and Company, Merck Serono, Sharp Dohme Company; serves on the speakers' bureau of Servier, Amgen, Novartis, Amgen, Novartis, Sanofi-aventis, Eli Lilly and Company, Merck Serono, Sharp Dohme Company; received travel reimbursement from Servier; is a consultant for Vactec and AstraZeneca; performs bone density testing for the Royal Melbourne Hospital (10% effort); receives royalties from the publication of the book Physical Activity and Bone Health; receives research support from Novartis, UCB, Sanofi-aventis, Eli Lilly and Company, Monash University, LaTrobe University, National Health and Medical Research Council of Australia, Victorian Cancer Agency and ANZ Trustees.Prof. O'Brien served as editorial board members of Epilepsia, Journal of Clinical Neuroscience and Epilepsy and Behavior; serves on the speakers' bureaus of UCB, Sanofi-aventis and SiGen and receives research support from UCB, Sanofi-aventis Jansen-Cilag, Royal Melbourne Hospital Neuroscience Foundation and Epilepsy Research Foundation and is funded by the NIH and NHMRC.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Solvay Pharmaceuticals, Inc., Abbott, Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Solstice Neurosciences, and Eli Lilly and Company; and honoraria from Novartis, the American Academy of Neurology, and the Movement Disorders Society. He serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders.Dr. Titulaer received research support from a KWF fellowship of the Dutch Cancer Society.Dr. Vincent served on the scientific advisory board for Patrick Berthoud Trust as Chair and member of the MGFA SAB; received honoraria from Baxter International; serves as Associate Editor for Brain; is a consultant for Athena Diagnostics; receives royalties from the publications of Clinical Neuroimmunology Blackwells Dale and Vincent Inflammatory and Autoimmune Disorders of the Nervous System in Children Mac Keith Press; receives revenue from Athena Diagnostics and RSR Ltd for MuSK antibodies for a patent, holds a patent for CASPR2, Lgi1, Contactin2 antibodies; receives research support from NIH, EU network grant, Euroimmun AG and Sir Halley Stewart Trust; performs neuroimmunology service for her department and is associated with Myasthenia Gravis Foundation of America.
1) Bleeding risk after stroke thrombolysis and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Brett Kissela interviews Dr. Michael Knoflach about his paper on an increased bleeding risk after stroke thrombolysis. Dr. Jennifer Fugate is reading our e-Pearl of the week about hummingbird sign in PSP. In the next part of the podcast Dr. Alberto Espay interviews Drs. Titulaer and Vincent about their lecture on clinical features, treatment and outcome of 500 patients with anti-NMDA receptor encephalitis. Next week, we will continue with our interview with Drs. Titulaer and Vincent. The participants had nothing to disclose except Drs. Kissela, Kiechl, Fugate, Espay and Mehler.Dr. Kissela serves on scientific advisory boards for Northstar Neuroscience and Allergan, Inc.; has received funding for travel and speaker honoraria from Allergan, Inc.; has received research support from NexStim and the NIH, and provides medico-legal reviews.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Solvay Pharmaceuticals, Inc., Abbott, Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Solstice Neurosciences, and Eli Lilly and Company; and honoraria from Novartis, the American Academy of Neurology, and the Movement Disorders Society. He serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders.Dr. Titulaer received research support from a KWF fellowship of the Dutch Cancer Society.Dr. Vincent served on the scientific advisory board for Patrick Berthoud Trust as Chair and member of the MGFA SAB; received honoraria from Baxter International; serves as Associate Editor for Brain; is a consultant for Athena Diagnostics; receives royalties from the publications of Clinical Neuroimmunology Blackwells Dale and Vincent Inflammatory and Autoimmune Disorders of the Nervous System in Children Mac Keith Press; receives revenue from Athena Diagnostics and RSR Ltd for MuSK antibodies for a patent, holds a patent for CASPR2, Lgi1, Contactin2 antibodies; receives research support from NIH, EU network grant, Euroimmun AG and Sir Halley Stewart Trust; performs neuroimmunology service for her department and is associated with Myasthenia Gravis Foundation of America.
If you experience any technical difficulties with this video or would like to make an accessibility-related request, please send a message to digicomm@uchicago.edu. Norbert Riedel, Corporate Vice President and Chief Scientific Officer of Baxter International, talks about the Chicago Innovation Pipeline, a collection of technologies available for licensing from 6 of the top research institutions in the Chicago region. The pipeline was developed by UChicagoTech for the 2010 BIO International Convention.
1) Imaging in acute stroke and 2) conflicts of interest: A personal perspective. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Brett Kissela interviews Dr. Yves Samson about his paper on diffusion-weighted MR imaging in acute stroke. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about posterior vermal split syndrome. In the next part of the podcast Dr. Matthew Wong interviews Dr. Joseph Martin for our Lesson of the Week about his paper on the pervasive influence of conflicts of interest. The participants had nothing to disclose except Drs. Kissela, Samson and Martin. Dr. Kissela served on the scientific advisory board for Allergan, Inc in 2009; served as a consultant for Allergan for 2-day meeting in 2009; received honoraria from CME program and unrestricted educational grants; received research support from the NIH [R01 NS 30678], [N01 NS 081588], [1Ul1 RR026314] and received compensation for reviewing records for several medical/legal cases regarding stroke. Dr. Samson is co-inventor of Neurinfarct software (Patent WO 2008/000973, issued 2008) currently owned by Intelligence in Medical Technologies, Paris; and holds stock in Intelligence in Medical Technologies. Dr. Martin has been on the Board of Directors at Baxter International for 8 years. For a short narrative describing this activity in greater detail, and the effect it had on Dr. Martin's activities, please see appendix e-1 at www.neurology.org
© 2020-2025 Ivy Podcast Discovery LLC
